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SUMMARY
The life sciences sector is the flagship for the Government’s Industrial Strategy. 
But who is leading the delivery of the Life Sciences Industrial Strategy? To 
whom are they accountable? What power do they have to harness Government 
departments and the NHS? These questions are at the heart of this inquiry.
The Business, Energy and Industrial Strategy Secretary and the Health and 
Social Care Secretary, together with the Prime Minister, have raised high 
expectations of the Life Sciences Industrial Strategy in the business, charity 
and academic sectors. Sir John Bell’s report, Life Sciences Industrial Strategy—A 
report to the Government from the life sciences sector has been welcomed widely. The 
importance of the life sciences sector to this country is well documented. Now 
is the time to convert that enthusiasm and commitment into action.
So far, Government action has been wholly inadequate. This inquiry has 
uncovered complicated arrangements for implementation, a lack of clear 
authority and accountability and a failure to engage the NHS effectively. In 
its turn, the NHS’s commitment to the strategy has so far been incoherent, 
uncoordinated and ineffective. This raises questions about the Government’s 
commitment to implementing the Life Sciences Industrial Strategy.
But all is not lost. Prompt and vigorous action by the Government can save the 
day. This strategy has already secured the commitment of the business, charity 
and academic communities. But the central role of the NHS in the life sciences 
means only the Government can take the lead.
We recommend that there should be sweeping simplification of the 
implementation arrangements: a single body, the Life Sciences Governing Body, 
should be responsible for the delivery of the Life Sciences Industrial Strategy. 
The Business, Energy and Industrial Strategy Secretary and the Health and 
Social Care Secretary must ensure it has the cross-Government backing it 
needs to do its work.
We recommend that the implementation of the Industrial Strategy, not least in 
the life sciences, should be scrutinised by a new Office for Industrial Strategy, 
reporting directly to Parliament.
The UK performs well in translating basic science into innovation. However, 
we heard compelling evidence that this country is less successful at growing 
small and medium-sized firms into larger companies. Sir John Bell sets the aim 
of four massive UK life sciences companies being created over the next 10 years. 
If this is to be realised, there must be a significant increase in the scale of patient 
investment capital available to innovative firms in the sector to enable them to 
grow over many years.
We are impressed by the Government’s initial response to the Patient Capital 
Review. Now this needs to be carried forwards. Further action is required to 
relax the rules on the allocation of pension fund assets to invest in the long-
term growth of research-intensive businesses. Proposals for these rules need to 
be backed by similar levels of commitment to the implementation of the Life 
Sciences Industrial Strategy.
The Government has an opportunity right now to get ahead of international 
competition. It can, and must, take bold steps to secure the future growth and 
expansion of the life sciences sector. This is even more vital as the UK prepares 
for life outside the European Union.

Life Sciences Industrial Strategy: 
Who’s driving the bus?
CHAPTER 1: INTRODUCTION
The life sciences sector
1. The UK life sciences sector is high-tech, research-intensive, scientifically 
diverse and innovative. It makes a significant contribution to the UK 
economy and to the health and wellbeing of the population. According to 
one analysis, it contributed £30.7bn to the economy in 2015 and supports 
482,000 jobs.1 As the UK prepares for life outside the European Union, it 
is essential that the UK continues to have a strong life sciences sector which 
can grow and expand quickly.
2. In this report, “life sciences” refers to the application of biology and 
technology to health improvement, including biopharmaceuticals, medical 
technology, genomics, diagnostics and digital health. This is the definition 
used by Sir John Bell in his report, Life Sciences Industrial Strategy—A report 
to the Government from the life sciences sector, which was central to our inquiry.2 
See paragraph 15 for a discussion of the scope of this definition.
3. The NHS is central to the UK life sciences sector and provides the UK 
with a unique selling point to offer to the life sciences industry and those 
who invest in it. The life sciences sector has a distinctive resonance with the 
population of the UK, principally because of its close links with healthcare 
and the NHS.
Background to inquiry
4. Successive governments have emphasised the importance of the life sciences 
sector. In recent years:
• The Coalition Government published a UK Life Sciences Strategy in 
2011, which was re-launched in 2013. The 2011 Life Sciences Strategy 
contained a number of “key actions”. These included an early access 
scheme for innovative new therapies, a £310m investment to support 
the commercialisation of research, an enhanced UK clinical trials 
gateway and high-level apprenticeships.3
• In 2014 the Government commissioned the Accelerated Access Review 
to consider speeding up access to innovative drugs, devices, diagnostics 
and digital products for NHS patients.4 The review was independently 
1 PwC, The Economic contribution of the UK Life Sciences industry (March 2017), p 4: https://www.abpi.
org.uk/media/1371/the_economic_contribution_of_the_uk_life_sciences_industry.pdf [accessed 23 
March 2018]
2 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector (August 
2017): https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/650447/Life 
SciencesIndustrialStrategy_acc2.pdf [accessed 23 March 2018]
3 Department for Business Innovation and Skills and Office for Life Sciences, Strategy for UK Life 
Sciences (December 2011): https://www.gov.uk/government/uploads/system/uploads/attachment_data 
/file/32457/11-1429-strategy-for-uk-life-sciences.pdf [accessed 23 March 2018]
4 Accelerated Access Review, Terms of Reference: https://www.gov.uk/government/organisations/
accelerated-access-review/about/terms-of-reference [accessed 23 March 2018]
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chaired by Sir Hugh Taylor (former Permanent Secretary at the then 
Department of Health) and supported by the Wellcome Trust. It 
published its final report in October 2016.5
• In November 2016 the Prime Minister, the Rt Hon Theresa May MP, 
announced a Patient Capital Review, to be led by HM Treasury, which 
would “identify barriers to access to long-term finance for growing 
firms”.6 We were aware from our previous work on the Government’s 
Industrial Strategy Green Paper7 that the availability of so-called 
“patient” capital8 in the UK was a problem for developing innovations 
and growing new companies in many sectors, including life sciences.
• In January 2017 the Government published a Green Paper on the 
Industrial Strategy (hereafter referred to as the Green Paper) which 
stated that Professor Sir John Bell would work on a strategy and early 
sector deal for life sciences, “to make the UK the best place in the 
world to invest in life sciences”.9
5. Against this background in July 2017 we decided to carry out an inquiry into 
Life Sciences and the Industrial Strategy. We knew that Government work 
in this area was ongoing and so were not surprised when, during our inquiry, 
the following events took place:
• Sir John Bell’s report, Life Sciences Industrial Strategy—A report to the 
Government from the life sciences sector10 was published on 30 August 
2017 (hereafter referred to as the Bell report);
• The Government responded to the final report of the Accelerated 
Access Review11 on 3 November 2017;
• On 22 November 2017 the Patient Capital Review: Industry Panel 
Response was published12 alongside the Government’s response to the 
financing growth in innovative firms consultation;13
5 Accelerated Access Review, Final Report: Review of innovative medicines and medical technologies (October 
2016): https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/565072/AAR_
final.pdf [accessed 23 March 2018]
6 HM Treasury and the Department for Business, Energy and Industrial Strategy, Terms of reference 
for the Patient Capital Review (November 2017): https://www.gov.uk/government/publications/patient-
capital-review/terms-of-reference-for-the-patient-capital-review [accessed on 23 March 2018]
7 Letter from Chairman of the Committee, Lord Selborne, to Secretary of State for Business, Energy 
and Industrial Strategy, 2 May 2017: https://www.parliament.uk/documents/lords-committees/
science-technology/Industrial-strategy/2017–05-02-Industrial-strategy-ltr-to-BEIS-Secretary-of-
state.pdf 
8 Patient capital is another name for long term capital. With patient capital, the investor is willing to 
make a financial investment in a business with no expectation of gaining a quick profit. Instead, the 
investor is willing to forgo an immediate return in anticipation of more substantial returns further in 
the future.
9 Department for Business, Energy & Industrial Strategy, Green Paper, Building our Industrial Strategy 
(January 2017): https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/6117 
05/building-our-industrial-strategy-green-paper.pdf [accessed 23 March 2018]
10 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector
11 Department for Health and Social Care and Department for Business, Energy and Industrial Strategy, 
Accelerated Access Review: response (3 November 2017): https://www.gov.uk/government/publications/
accelerated-access-review-response [accessed 23 March 2018]
12 Patient Capital Review Industry Panel, Industry Panel Response (22 November 2017): https://www.
gov.uk/government/uploads/system/uploads/attachment_data/file/661397/PCR_Industry_panel_
response.pdf [accessed 23 March 2018]
13 HM Treasury, Financing growth in innovative firms: consultation response (22 November 2017): https://
www.gov.uk/government/uploads/system/uploads/attachment_data/file/661398/Patient_Capital_
Review_Consultation_response_web.pdf [accessed 23 March 2018]
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• On 27 November 2017 the Government published its Industrial 
Strategy White Paper, Industrial Strategy: building a Britain fit for the 
future14 (hereafter referred to as the White Paper); and
• On 6 December 2017 the Government published the first phase of the 
Life Sciences Sector Deal.15
Our inquiry
6. The Government has not set out clearly which documents comprise the Life 
Sciences Industrial Strategy. We and most of our witnesses understand Sir 
John Bell’s report and the Life Sciences Sector Deal to together comprise the 
strategy. As such, they represent the first sector strategy16 produced under the 
present Government’s Industrial Strategy. It provides a benchmark for other 
sector strategies and deals which will follow. It represents an opportunity 
to provide a successful model, aspects of which can be replicated in other 
sectors. Conversely, if it fails the whole Industrial Strategy will be called into 
question.
7. Most of the evidence raised the same important issues which we have sought 
to draw out. We have focused on those issues that require immediate action 
to ensure the development and expansion of the UK’s life sciences sector. We 
believe this will be most helpful to the Government as it implements the Life 
Sciences Industrial Strategy.
Structure of our report
8. Much of the evidence we received, whilst broadly welcoming Sir John Bell’s 
report, related to the challenges of implementation. In Chapter 2 we consider 
these challenges and make recommendations. In Chapter 3 we consider the 
role of the NHS and how it can both benefit from the strategy and contribute 
to its success. Chapter 4 considers action needed to increase access to finance 
for companies within the sector. Chapter 5 concentrates on the challenges of 
ensuring the sector has access to a skilled workforce. The evidence showed 
that the UK’s excellent science base attracts private sector investors in the 
life sciences from around the world. In Chapter 6 we consider how this can 
be maintained and enhanced in the future.
Acknowledgements
9. We received a large volume of oral and written evidence in response to 
our call for evidence (see Appendix 3). On 31 October 2017 we visited the 
Francis Crick Institute and took oral evidence there from Sir Paul Nurse, 
Director and Chief Executive, and five scientists based at the Institute. We 
are grateful to Sir Paul Nurse and the staff of the Francis Crick Institute, 
and to all those who gave evidence to the inquiry. We are also grateful to our 
specialist adviser for this inquiry, Professor Graeme Reid, Chair of Science 
and Research Policy at University College London, for his expertise and 
14 Department for Business, Energy & Industrial Strategy, Industrial Strategy: Building a Britain fit for 
the future, Cm 9528, 27 November 2017: https://www.gov.uk/government/publications/industrial-
strategy-building-a-britain-fit-for-the-future [accessed 23 March 2018]
15 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal (December 2017): https://www.gov.uk/government/uploads/system/uploads/attachment_
data/file/665452/life-sciences-sector-deal-web-ready-version.pdf [accessed 12 April 2018]
16 In this report “Life Sciences Industrial Strategy” refers to the Bell report and the Life Sciences Sector 
Deal together. Where we refer to just one of these documents we use the terms “Bell report” and 
“sector deal”.
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enthusiasm. We are also grateful to the Committee staff who worked on the 
inquiry: Anna Murphy (Clerk); Dr Daniel Rathbone (Policy Analyst); and 
Cerise Burnett-Stuart (Committee Assistant).
Government response and next steps
10. We look forward to receiving a written response to this report from the 
Government and we will seek a debate in the House as soon as possible 
thereafter.
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CHAPTER 2: CHALLENGES OF IMPLEMENTATION
11. We welcome the Bell report, as did most of those who gave evidence to this 
inquiry. Whilst it does not contain proposals for implementation, it provides 
an analysis of and a vision for the life sciences sector. It was followed by the 
publication of the first phase of the Life Sciences Sector Deal on 6 December 
2017.17
12. If implemented—across the relevant Government departments, the NHS, 
industry, academia, charities and the financial sector—the Life Sciences 
Industrial Strategy will make a major contribution to the future economic 
prosperity of the UK. Much effort has gone into creating the strategy and 
much expectation has been raised personally by the Rt Hon Greg Clark MP, 
Secretary of State for Business, Energy and Industrial Strategy, and the Rt 
Hon Jeremy Hunt MP, Secretary of State for Health and Social Care.
13. It became clear to us during this inquiry that the Life Sciences Industrial 
Strategy stands little chance of success without a detailed plan for 
implementation and clear lines of authority, responsibility and accountability. 
The role of the NHS in the life sciences sector (which we consider in detail 
in Chapter 3) means that the industry-driven approach the Government has 
adopted with other sectors to implement the Industrial Strategy will not work 
and the Government must drive the implementation of the Life Sciences 
Industrial Strategy.
The Bell report
14. The Bell report contains recommendations for the Government and the 
life sciences sector.18 It has been welcomed by the Government and was 
accompanied by a series of announcements of funding from the Secretary 
of State for Health and Social Care and the Secretary of State for Business, 
Energy and Industrial Strategy.19
15. In the foreword to his report, Sir John Bell indicated that it dealt with the 
health life sciences sector, which he defined as “the application of biology and 
technology to health improvement, including biopharmaceuticals, medical 
technology, genomics, diagnostics and digital health”.20 We are aware that 
the term could also include, for example, biotechnology, agriculture, plant 
science, animal science and climate change mitigation and adaptation. The 
exclusion of these runs the risk that they will be neglected.
16. We recommend that the Government should identify and publish 
the areas of life sciences not covered by the Bell report and the Life 
Sciences Sector Deal. Businesses and investors in parts of the life 
sciences not covered will then know the areas in which they are free 
to propose further sector deals.
17 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal 
18 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector
19 HM Government, Press release: ‘Sir John Bell to unveil industry-led proposals to build UK’s status as 
world leader in life sciences’, 30 August 2017: https://www.gov.uk/government/news/sir-john-bell-to-
unveil-industry-led-proposals-to-build-uks-status-as-world-leader-in-life-sciences [accessed 4 April 2018]
20 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 3
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17. While the Government has talked of having a “life sciences industrial 
strategy”21 and “supports the vision and aims of the [Bell report]”22 it has 
avoided any explicit acceptance of responsibility for the delivery of all of Sir 
John’s recommendations. The Rt Hon the Lord Henley, Parliamentary Under 
Secretary of State at the Department for Business, Energy and Industrial 
Strategy (the BEIS Minister), told us that “it is Sir John Bell’s report … it 
is not a Government report”.23 He also told us the Government is bound by 
the Life Sciences Sector Deal24 and that he would “endorse some of Sir John 
Bell’s ambitions without saying that they are Government targets”.25 The 
Government reiterated this point in its supplementary written evidence:
“The Strategy is not a government document; it is a sector (which 
includes industry, charities and academia) document which makes 
recommendations to Government on ways to ensure the UK remains a 
top-tier global hub for clinical research and medical innovation.”26
18. There is some ambiguity about the status of the Bell report and its 
implementation. We recommend that the Government should adopt 
the Bell report in full and provide an implementation plan to which 
it and the other stakeholders can be held to account.
Importance of implementation
19. Whilst the evidence we heard welcomed the Bell report, many witnesses 
pointed out that it did not contain the detail required for its successful 
implementation.27 We heard different views on how the Bell report and the 
Life Sciences Sector Deal should be implemented but all witnesses agreed 
that a detailed implementation plan is vital to their success.
20. Witnesses pointed to the 2011 Life Sciences strategy as an example of 
what can happen if a strategy is not implemented effectively. The 2011 
strategy was considered a partial success by many witnesses but some of its 
recommendations were not implemented because of a lack of an adequate 
implementation plan and clear accountability. Roche, a Swiss multinational 
healthcare company that operates in the UK, told us that the absence of 
timelines for implementation may have contributed to problems with 
the implementation of the 2011 Life Sciences strategy.28 GSK, a British 
pharmaceutical company, echoed that, saying that “implementation where it 
happened was piecemeal and did not follow the holistic, joined-up structure 
of the Strategy”.29 The Association of the British Pharmaceutical Industry 
(ABPI) told us that based on their experience of the previous strategy the 
following would help ensure the success of the Life Sciences Industrial 
Strategy:
21 Q 283 (Lord Henley)
22 Supplementary written evidence from HM Government (LSI0132)
23 Q 276 (Lord Henley)
24 Ibid.
25 Q 275 (Lord Henley)
26 Supplementary written evidence from HM Government (LSI0132)
27 Written evidence from British Heart Foundation (LSI0023), Q 14 (Prof James Stirling CBE), Q 49 
(Mike Thompson) and Q 60 (Sir Paul Nurse)
28 Written evidence from Roche (LSI0073)
29 Written evidence from GSK (LSI0115)
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“A clear plan with responsibilities and milestones.
A governance structure that is able to hold Government, NHS England, 
research partners and the life sciences sector (industry and non-profit) 
to account.
Annual public reports of progress.”30
21. The Government initiated the Industrial Strategy, defined its framework and 
is publishing documents relating to it. While industry needs to be involved in 
implementing the Bell report, only the Government can lead the process of 
drawing up an implementation plan against which the Government, the NHS 
and industry can be held accountable. The implementation plan can then be 
delivered by an independent body, as suggested by Dr Michael Hopkins, 
Senior Lecturer at the Science Policy Research Unit, Sussex University, and 
GSK.31 GSK added that this body should be made up of a wide range of 
stakeholders. This needs to be done quickly because, in the words of Sir 
John Bell, it is “crucial … to make sure that we maintain momentum [and] 
deliver the things in the report”.32 The BEIS Minister agreed, saying that 
“publishing the industrial strategy on its own is not enough; it is about how 
we maintain the momentum”.33 It is disappointing therefore that the Minister 
also told us that he could not guarantee when we might start to see changes 
as a result of the Bell report and the Life Sciences Sector Deal.34
22. The evidence we have heard, particularly about the failings of the 2011 
Life Sciences Strategy, has highlighted the importance of a detailed 
implementation plan that contains timelines, milestones and metrics 
for measuring success. The Bell report provides the vision for the 
sector; the Government must now work with stakeholders to draw up 
an implementation plan.
Sector Deal
23. The White Paper describes sector deals as “partnerships between the 
Government and industry on sector-specific issues [that] can create 
significant opportunities to boost productivity, employment, innovation and 
skills”.35
24. The Government told us that “the publication of the [Bell report] on 
30th August marked the start of negotiations on a Sector Deal between 
Government and the life sciences sector”.36 A Life Sciences Sector Deal was 
subsequently published on 6 December 2017.37
25. Erik Nordkamp, Chair of the American Pharmaceutical Group (APG), 
told us that in countries with successful life sciences sectors government 
and industry work together in partnership, rather than in a transactional 
30 Written evidence from the Association of the British Pharmaceutical Industry (ABPI) (LSI0102)
31 Q 169 (Dr Michael Hopkins) and written evidence from GSK (LSI0115)
32 Q 199 (Sir John Bell)
33 Q 274 (Lord Henley)
34 Ibid.
35 HM Government, Industrial Strategy: Building a Britain fit for the future, Cm 9528, 27 November 2017, 
p 192: https://www.gov.uk/government/publications/industrial-strategy-building-a-britain-fit-for-the- 
future [accessed 22 March 2018]
36 Q 276 (Lord Henley)
37 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal
12 LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
way, as they have in the UK in the past.38 The BEIS Minister told us that 
the Industrial Strategy “is fundamentally about a partnership between 
Government and industry”.39
26. The Government describes the Life Sciences Sector Deal as bringing together 
government, universities, charities and more than 25 businesses to make a 
joint commitment to invest in all parts of the UK.40 However the Sector 
Deal is presented as two separate lists: what the sector is doing and what the 
Government is doing. There is little sign of joining up and no distinction 
between what would have happened anyway and what has been initiated 
specifically by the Bell report. The Government remains focused on a 
transactional relationship with rather than a strategic partnership 
with the life sciences sector. This is inadequate.
27. MSD, an American pharmaceutical company investing in the UK, told us 
that “it is important the Sector Deal has clear metrics and deliverables in 
place in order to measure implementation, which includes clear accountability 
across all stakeholders”.41 The Government’s written evidence stated:
“Once agreed, the Sector Deal will include an implementation plan, 
with metrics, governance and oversight arrangements to ensure that 
success can be measured against objectives.”42
28. No such implementation plan is included in the Sector Deal as published and 
it does not contain any metrics, milestones or timeframes for implementation. 
The Sector Deal says that a Sector Deal Oversight board would meet in 
January 2018 to agree an implementation plan. We are not aware that this 
meeting took place.
29. The Government said that some of the Bell report’s recommendations may 
not fit in to a sector deal and “it is right that the Government identifies 
these and proposes alternative policy development and implementation 
mechanisms”.43
30. The first phase of the Life Sciences Sector Deal as published does not 
constitute a plan that will ensure the successful implementation of the 
Bell report. The Sector Deal is designed along the lines of those for 
other sectors. It does not take account of the important and central 
role of the NHS which necessitates greater Government involvement 
in the life sciences sector.
31. We are disappointed that the Sector Deal does not contain the metrics, 
governance and oversight arrangements that the Government 
had promised in its written evidence. It lacks operational detail on 
how different arms of the Government will work together towards 
a single objective. Furthermore, it does not provide information 
about the provision and allocation of resources for many strands of 
implementation (particularly those involving the NHS).
38 Q 181 (Erik Nordkamp)
39 Q 272 (Lord Henley)
40 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal
41 Written evidence from MSD (LSI0100)
42 Written evidence from HM Government (LSI0111)
43 Supplementary written evidence from HM Government (LSI0132)
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Implementation bodies
32. When we asked Ministers what bodies would be responsible for implementation 
they seemed to conflate operational arrangements for implementation with 
oversight, naming a number of bodies but giving no information about 
the operational arrangements that will be vital to the timely and effective 
implementation of the Bell report or the Life Sciences Sector Deal.44 In Box 
1 we list the bodies which the Government has named.
33. We asked the Government for more information on the various proposed 
bodies. This information was provided in supplementary written evidence. 
It was inadequate because:
• The full membership of the Life Sciences Industrial Strategy 
Implementation Board has not been finalised;
• The draft terms of reference do not provide sufficient detail on how the 
Life Sciences Industrial Strategy Implementation Board will function:
• It does not explain how the Board will interact with the Life Sciences 
Council or the numerous other bodies that are to sit under the council 
(see Box 1).45
Box 1: Government bodies related to Life Sciences
Life Sciences Council
Sector Deal Oversight Board
Life Sciences Industrial Strategy Implementation Board
EU Relationship Group
Health Technology Partnership
Medicines Manufacturing Industry Partnership
Innovation, Research and Clinical Data Group
Accelerated Access Collaborative
Patient Access Partnership
Independent Industrial Strategy Council
Source: Supplementary written evidence from HM Government (LSI0132), Department for Business, Energy & 
Industrial Strategy and Office for Life Sciences, Life Sciences Sector Deal (December 2017): https://www.gov.uk/
government/uploads/system/uploads/attachment_data/file/665452/life-sciences-sector-deal-web-ready-version.
pdf [accessed 12 April 2018] and HM Government, Industrial Strategy: Building a Britain fit for the future, Cm 
9528, 27 November 2017: https://www.gov.uk/government/publications/industrial-strategy-building-a-britain-fit-
for-the-future [accessed 23 March 2018]
44 Q 274 (Lord Henley, Lord O’Shaughnessy)
45 Supplementary written evidence from HM Government (LSI0132)
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34. As a minimum, the Government must clarify urgently:
• Which bodies are responsible for each aspect of operational 
delivery of implementation;
• The membership of these bodies;
• Their terms of reference; and
• The authority these bodies will have to coordinate policy and 
delivery across Government departments.
In paragraph 49 we set out our proposals for the implementation of the 
strategy which go beyond the minimum standards set out above.
Interaction with the wider Industrial Strategy
35. The Life Sciences Industrial Strategy is one element of the Government’s 
wider Industrial Strategy. We received evidence from the Association of 
Medical Research Charities that the “alignment between the overarching 
industrial strategy and the Sector Deal for the Life Sciences is vital”46 
and that it is important that “the Life Sciences Strategy, wider Industrial 
Strategy, and regional strategies are implemented in a co-ordinated and 
complementary manner”.47
36. Some aspects of the Life Sciences Industrial Strategy such as skills, 
immigration and finance lie, as the Rt Hon the Lord Heseltine CH told 
us, outside the responsibilities of BEIS and the Department of Health and 
Social Care (DHSC), “Government should think across, not just within, 
the disciplines”.48 The ABPI explained that collective action across the 
Government was vital because, “a pick and mix approach delivers a patchy 
environment which may not compete as well with other countries also seeking 
to attract investment”.49 We focus on skills and immigration in Chapter 5 
and on finance in Chapter 4.
37. The Government should propose and obtain agreement from all 
stakeholders to an implementation plan for the Bell report and 
the Life Sciences Sector Deal, which must be integrated with the 
implementation of the overall Industrial Strategy.
Leadership, monitoring, accountability and oversight
38. Many witnesses told us that leadership, clear accountability for and oversight 
of the implementation of the Life Sciences Industrial Strategy (as opposed 
to the actual process of implementation) are important if the strategy is to 
succeed. The Campaign for Science and Engineering told us that “the early 
progress made in the 2011 strategy was hindered by a lack of accountability 
and loss of leadership”.50
39. We were told that ultimate responsibility for the strategy should lie with the 
two Secretaries of State; for Business, Energy and Industrial Strategy and 
Health and Social Care. Professor Chris Whitty, Chief Scientific Adviser, 
46 Written evidence from Association of Medical Research Charities (AMRC) (LSI0098)
47 Written evidence from Loughborough University (LSI0033)
48 Q 143 (Lord Heseltine)
49 Written evidence from ABPI (LSI0102)
50 Written evidence from Campaign for Science and Engineering (CaSE) (LSI0076)
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Department of Health and Social Care and Interim Government Chief 
Scientific Adviser, told us “the role of the Secretary of State [for Health and 
Social Care] … is going to be absolutely essential … if you excluded them 
from having a major role in this the chances of success would be very low”.51 
Sir John Bell echoed this point: “if the two Secretaries of State do not have 
the time to commit to this, it [is] probably not worth doing”.52
40. The BEIS Minister told us that the proposed Life Sciences Council, co-
chaired by the two Secretaries of State along with the chief executive officer 
of the pharmaceutical company AstraZeneca, will provide “Cabinet level 
oversight”.53
41. It has not yet been announced who the remaining members of the Council 
will be, the terms on which they will be appointed, what authority the Council 
will have over other Government departments or what its terms of reference 
will be. The BEIS Minister told us that “the appointments will be made by 
Government on the advice of industry and others, to make sure that we get a 
broad range of people covering … industry … the NHS, academe and other 
areas”.54 He said that the first meeting of the Council would probably not 
happen until April 2018.55
42. An independent Industrial Strategy Council is to provide oversight of the 
wider Industrial Strategy, including the Life Sciences Industrial Strategy, 
but there is little detail in the White Paper of who will appoint this Council, 
the authority it will be given, its terms of reference and to whom it will be 
accountable. The BEIS Minister told us that “it will not be a statutory body” 
and “it will have the power to make reports and recommendations and to tell 
us where we have got it wrong”.56 He was unable to say who would serve on 
the Council.57
43. This uncertainty is unsatisfactory. We set out our proposals for oversight of 
the Industrial Strategy in paragraph 51.
Devolved administrations
44. Many witnesses told us that the devolved administrations must be involved 
in implementing the strategy. The Medical Schools Council (MSC) and the 
Association of UK University Hospitals (AUKUH) told us that it will be 
“important that attention is paid to the NHS in all four devolved nations for 
the impact of this report to be realised”.58 The ABPI and the Academy of 
Medical Sciences also told us that engagement and collective action with the 
devolved administrations was important.59
45. We were disappointed to hear from the Life Sciences Scotland Industry 
Group, which is responsible for the Scottish Life Sciences Strategy, published 
in February 2017, that the Office for Life Sciences is “currently not strongly 
51 Q 162 (Prof Chris Whitty)
52 Q 199 (Sir John Bell)
53 Supplementary written evidence from HM Government (LSI0132)
54 Q 274 (Lord Henley)
55 Ibid.
56 Q 276 (Lord Henley)
57 Q 274 (Lord Henley)
58 Written evidence from Medical Schools Council and the Association of UK University Hospitals 
(LSI0081)
59 Written evidence from ABPI (LSI0102) and Academy of Medical Sciences (LSI0107)
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enough engaged with the regions and devolved administrations”.60 Lord 
O’Shaughnessy, Parliamentary Under Secretary of State at the Department of 
Health and Social Care (the Health Minister), said he had not had discussions 
with the devolved administrations about the life sciences strategy.61
Our proposal for implementation and oversight of the Life Sciences 
Industrial Strategy
46. The Government must clarify exactly which documents comprise the 
Life Sciences Industrial Strategy. This is still unclear and successful 
implementation cannot be achieved until it is clarified. Most witnesses 
told us that they understand the strategy to be the Bell report and the 
Life Sciences Sector Deal and we have adopted that definition.
47. Implementation and oversight are vital to the success of both the 
Life Sciences Industrial Strategy and the wider Industrial Strategy. 
The Government’s plans for implementation and oversight do not 
provide an effective model and as set out are a recipe for failure. 
Not only do they lack clarity and detail, they fail adequately to take 
account of the central role of the NHS in the life sciences sector.
48. In the following paragraphs we set out our proposal for delivery, 
accountability and leadership which, drawing on the Government’s 
model and suggestions made to us by witnesses, sets out a clear 
and effective system for implementing the Life Sciences Industrial 
Strategy. See also Figure 1, which shows our proposal in the form of 
a diagram.
Life Sciences Governing Body
49. The Government’s system for implementation is too complex 
and duplicative. We recommend that, in place of the Life Sciences 
Implementation Board and the Life Sciences Council, there should 
be a single body (referred to hereafter as the Life Sciences Governing 
Body) responsible for the delivery of the Life Sciences Industrial 
Strategy, which should:
• Be co-chaired by the Secretary of State for Business, Energy 
and Industrial Strategy and the Secretary of State for Health 
and Social Care with executive leadership from Sir John Bell as 
Life Sciences Champion;
• Meet frequently;
• Have a membership of about 12, including senior figures from 
the NHS, industry, academia and the charities sector;
• Take the lead in drawing up an implementation plan, with clear 
milestones, timelines and criteria for success;
• Task subordinate working groups with the actual operational 
delivery of specific areas of the plan; and
• Report to a Cabinet Committee.
60 Written evidence from Life Sciences Scotland Industry Group (LSI0042)
61 Q 284 (Lord O’Shaughnessy)
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50. The Secretaries of State for Business, Energy and Industrial 
Strategy and Health and Social Care should ensure the Life Sciences 
Governing Body has the backing required to do its work and should 
take responsibility for the cross-Government aspects of the strategy.
Oversight—Office for Industrial Strategy
51. We recommend the creation of a new statutory body, the Office 
for Industrial Strategy (OfIS) with the authority to scrutinise the 
implementation of the wider Industrial Strategy and the Life Sciences 
Industrial Strategy and to publish its findings. The remit of the OfIS 
should cover the implementation of the Patient Capital Review. The 
OfIS would be accountable to Parliament and report annually on 
progress made by each Government department in implementing 
the Industrial Strategy.
Figure 1: Our proposal for implementation and oversight of the Life 
Sciences Industrial Strategy
Accountable to
Other sectors’ 
implementation
bodies (not within the 
remit of this report)
Life Sciences 
Governing Body
Cabinet Committee
on Industrial Strategy Oﬃce for 
Industrial Strategy
(OfIS)
Independent Scrutiny
Provides independent scrutiny 
of the implementation of the 
Industrial Strategy
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CHAPTER 3: ROLE OF THE NHS
52. The Bell report says the NHS is “potentially an enormous asset for those 
attempting to discover and develop new, innovative products and to properly 
test their utility in a healthcare system”.62 Furthermore, exploiting NHS data 
has the potential greatly to benefit patient care, UK firms and the economy 
more widely. The NHS differentiates the UK from the rest of the world 
providing a unique selling point to the life sciences sector.
53. We heard repeatedly that the NHS is vital to the successful implementation 
of the Life Sciences Industrial Strategy and the Health Minister told us that 
“the NHS part is critical” to the Strategy.63 However, we heard consistent 
evidence, including from the NHS itself, that the NHS does not currently 
have the capacity to rise to the challenge of implementation.64 Concerns 
were also raised about deeply embedded characteristics of the NHS—such 
as its highly federated structure—which limit its ability to adopt successful 
innovations and to diffuse them throughout the organisation. However, the 
Health Minister said he “would not call [the NHS] a weak player … I think 
it is a willing player”.65
Co-ordination of NHS bodies
54. We heard that there is a lack of coordination between NHS bodies including—
the DHSC, NHS England, NHS Improvement, foundation trusts and 
Clinical Commissioning Groups—which will be a barrier to implementing 
the Life Sciences Industrial Strategy. The evidence suggests there have been 
no high-level discussions on implementing the strategy across the NHS. 
When it was put to NHS Improvement that there was no co-ordinated 
activity or discussions related to the Life Sciences Industrial Strategy and 
its implementation within the NHS, Miles Scott, Improvement Director at 
NHS Improvement, told us “[the Strategy] is not the centrepiece of what the 
NHS is trying to do. It is not a significant part of our engagement with NHS 
trusts and NHS foundation trusts in and of itself”.66
55. Sir John Bell told us that:
“The senior people I have interacted with … want to see the health 
service deal with [the uptake and spread of innovation]; … The problem 
is … it is not clear who is driving the bus … Whoever is driving the bus, 
the windscreen wipers do not work and the exhaust is falling off.”67
NHS and innovation
56. Almost all the evidence we received said that the NHS was poor at adopting 
innovation at scale. GSK told us that the NHS “offers a very powerful 
mechanism to both stimulate and benefit from … innovation” but “we are 
a long way from realising the full potential of the NHS”.68 AstraZeneca said 
that for the UK to “retain and attract more and new investment … companies 
need to see increased use by the NHS of the resulting innovations”.69
62 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 50
63 Q 273 (Lord O’Shaughnessy)
64 Q 97 (Ian Dodge), Q 61 (Sir Paul Nurse), Q 207 (Sir John Bell), Q 56 (Sir Robert Lechler), Written 
evidence from NHS Innovations South East (LSI0010), P3 Medical Ltd (LSI0029), the Association 
of British Healthcare Industries (ABHI) (LSI0091) and Birmingham Health Partners (LSI0034)
65 Q 279 (Lord O’Shaughnessy)
66 Q 261 (Miles Scott)
67 Q 225 (Sir John Bell)
68 Written evidence from GSK (LSI0115)
69 Written evidence from AstraZeneca (LSI0117)
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57. Smaller businesses that work with the NHS also criticised its uptake of 
innovation. Mark Campbell CBE, Senior Manager at Randox Laboratories, 
told us that if Randox Laboratories “had to survive on the income from 
innovation, we could not do it. The issue is … the NHS … and its ability 
to adopt quickly”.70 The Health Minister acknowledged that “one of the 
concerns is not that innovations cannot get a foothold but that they do 
not often get beyond that foothold. They might be trialled in a few [NHS] 
Trusts or departments, but then they are not spread”.71 Professor Dame Sally 
Davies, Chief Medical Officer for England, said that the fact the NHS is not 
a single body exacerbated the problem for industry, making the spread of 
innovation more difficult.72
58. NHS England told us that it sees innovations as either ‘additive’ or 
‘substitutive’. Additive innovations are additional to existing services. 
Substitutive innovations replace existing services with a better, more efficient 
service.73 They told us that “even if additive inventions are cost-effective, 
they may not always be affordable within the NHS budget”. However, if 
innovations are substitutive and “are proven to be genuinely cost-saving or 
cost-neutral in real world trials” they are much easier to adopt, particularly 
when budgets are constrained.74 Randox Laboratories said that “silo-
budgeting” within the NHS could prevent even substitutive innovations 
from being adopted.75
59. Sir John Bell told us that one of the reasons why the NHS struggles with 
adopting innovations is because “ [it is] struggling to do even simple things 
well. The idea that you are going to put a whole lot of this really sexy 
techrelated stuff on top is challenging”.76 He also told us that the current 
structure of the NHS does not allow discussions to take place about what 
existing treatments or pathways should be stopped to allow the introduction 
of new innovations: ““You want the new drug. Okay. If you, the doctors, 
want the new drug, what are you going to give up? It must add better value 
than you get from the existing thing”. I do not think we do that”.77
60. Ian Dodge, Director of Innovation at NHS England, told us that the challenge 
was to connect innovation and life sciences with NHS core business, in the 
face of external constraints including “living within … our toughest funding 
settlement”. He went on to say that this “means making sure that, when we 
are supporting industry … we are really clear about what the benefits will be 
to the NHS”.78
61. The current structure of the NHS stifles innovation. A focus on cost-
control and a lack of co-ordination between the various bodies that 
make up the NHS means that the adoption and spread of innovations 
is not given the priority it requires. Unless the NHS’s ability to adopt 
and spread innovations is improved, it will not be able to play a full 
role in the implementation of the Life Sciences Industrial Strategy. 
This will endanger the success of the strategy.
70 Q 27 (Mark Campbell CBE)
71 Q 273 (Lord O’Shaughnessy)
72 Q 164 (Dame Sally Davies)
73 Written evidence from NHS England (LSI0114)
74 Ibid.
75 Written evidence from Randox Laboratories Ltd (LSI0063)
76 Q 219 (Sir John Bell)
77 Q 222 (Sir John Bell)
78 Q 97 (Ian Dodge)
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62. NHS England and NHS Improvement must give the highest priority 
to the adoption and spread of innovation throughout the NHS. They 
should work together to align their strategies to maximise the 
chances of success in this area.
Existing initiatives
63. We heard about initiatives such as the Academic Health Science Networks 
(AHSNs) and the Small Business Research Initiative (SBRI), which aim to 
help with the adoption and spread of innovation in the NHS.
64. Since 2013, NHS England has funded a national network of 15 AHSNs 
to act as a bridge between academia, industry and the NHS, supporting 
researchers and innovators to deliver change in the NHS. NHS England 
told us that they are the “NHS distribution network for innovation”.79 P3 
Medical Ltd, a medical device manufacturer, welcomed the AHSNs and 
thought their role should be expanded.80
65. There was however widespread concern that AHSNs do not have sufficient 
resources to operate effectively. Professor Sir Robert Lechler, President 
of the Academy of Medical Sciences and Executive Director of King’s 
Health Partners Academic Health Sciences Centre, told us: “I do not think 
[Academic Health Science Networks] have the resources to [drive adoption of 
innovations], but I believe they genuinely have the opportunity to do that”.81 
The AHSN Network echoed this point, “AHSNs are bodies put in place 
to support [changes in practice and clinical pathways]: however sufficient 
funding and encouragement for those rolling out treatment options have not 
been built around this structure”.82
66. NHS Innovations South East suggested an audit to assess the effectiveness 
of AHSNs.83 The Health Minister said that there are “probably too 
many pathways” for innovation in the NHS and that “there needs to be a 
simplification and rationalisation so that we can get those products not only 
started and piloted, but diffused”.84
67. The Cell and Gene Therapy Catapult told us about research commissioned 
by the UK BioIndustry Association (BIA) in March 2017, which found that 
“staff across the NHS are generally unaware of the challenges around the 
adoption of innovation and have little or no awareness of previous government 
initiatives aimed at addressing these challenges and improving the uptake of 
new treatments”.85
68. After we heard evidence from NHS England they published a paper 12 
Actions to Support and Apply Research in the NHS in November 2017. We view 
this as a step forward in the involvement of the NHS in the life sciences 
strategy and welcome two of the actions:
79 Written evidence from NHS England (LSI0114)
80 Written evidence from P3 Medical Ltd (LSI0029)
81 Q 56 (Sir Robert Lechler)
82 Written evidence from AHSN (Academic Health Science Networks) Network (LSI0028)
83 Written evidence from NHS Innovations South East (LSI0010)
84 Q 276 (Lord O’Shaughnessy)
85 Written evidence from the Cell and Gene Therapy Catapult (LSI0108)
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• “Back AHSNs to become the main local NHS delivery vehicle for 
spreading innovations.
• Review and simplify the number of different national innovation 
projects and programmes.”86
Financial incentives for innovation
69. Dame Julie Moore, Chief Executive of University Hospitals Birmingham 
NHS Foundation Trust, told us that financial incentives, such as best 
practice tariffs for trusts that show rapid adoption of innovations, could be a 
way forward.87 Professor Keith McNeil, Chief Clinical Information Officer 
Health and Social Care at NHS England, said that, “We have to incentivise 
[innovation] by making it as important as your financial outcomes and 
patient outcomes… If you measure it and make it part of a [key performance 
indicator] for a CEO and a hospital trust, it will happen”.88
70. The Health Minister told us that the innovation and technology tariff 
“rewards the uptake of innovation” but that this was one of many possible 
routes to innovation uptake.89 Sir John Bell told us that “the activation energy 
to get innovation into a system is very real and it costs money. Even though 
the effectiveness of savings may be seen over time, it costs money to get it in 
place”.90 It might help increase the uptake of innovations if financial help is 
available to trusts to help them overcome this “activation energy”.
71. The NHS should give greater priority to the uptake and spread of 
innovation and to rewarding clinicians and managers who make 
such adoption successful. We recommend that the Government 
should explore how it can offer financial incentives to those NHS 
trusts that adopt and spread proven innovations.
72. The Academic Health Science Networks have a role to play in driving 
the adoption at pace and scale of innovations throughout the NHS. 
Where they are working well AHSNs should be further developed. 
AHSNs should have a clear link to the Life Sciences Governing Body 
(see paragraph 49).
73. We recommend that NHS England should mandate the uptake of 
those innovations that have been shown to improve patient outcomes 
and provide good value for money.
Healthcare data
74. The Bell report says that “one of the most important resources held by 
the UK health system is data generated by the 65 million people covered 
within it”.91 Witnesses told us that the exploitation of healthcare data, with 
adequate privacy safeguards, is one of the big commercial and healthcare 
opportunities identified in the strategy. Professor Bryan Williams, Director 
of R&D at University College London Hospitals, explained:
86 NHS England, 12 Actions to Support and Apply Research in the NHS (November 2017), p 4: https://www.
england.nhs.uk/wp-content/uploads/2017/11/08-pb-30-11-2017-supporting-and-applying-research.
pdf [accessed 1 February 2018]
87 Q 45 (Dame Julie Moore)
88 Q 98 (Prof Keith McNeill)
89 Q 276 (Lord O’Shaughnessy)
90 Q 222 (Sir John Bell)
91 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 56
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“Almost the entire population is covered by a single healthcare provider 
from birth to death, and we have comprehensive records somewhere on 
everybody. The ability to utilise that for drug discovery, monitoring the 
effectiveness of treatments and understanding the underlying basis of 
disease is enormous, and we have not realised that potential.”92
75. Professor McNeil explained that it is not just patient data from clinical care 
that the NHS has access to but data about clinical trials, which if harnessed 
could shorten clinical trials and improve the uptake of new treatments.93 The 
Health Minister said that using existing NHS data could “radically reduce 
the cost of clinical trials”.94
76. Witnesses highlighted several problems that needed to be overcome to realise 
fully the potential of healthcare data. Professor McNeil told us that NHS 
data “is not structured; it is not standardised; it is not linked; it is not joined 
up” and this makes it difficult to realise its benefits.95
77. Whilst maintaining privacy and ensuring informed consent from patients 
are important, they could be potential barriers to using healthcare data. 
The Royal Academy of Engineering told us that “informed consent and 
confidentiality are clearly of particular importance … it is vital that a patient-
centric approach is taken to discuss and explain the benefits to patients and 
society of sharing data, alongside any risks”.96
78. Dame Julie Moore said that, whilst the public argument about the use of 
NHS data for research had not yet been won, since University Hospitals 
Birmingham NHS Foundation Trust introduced digital systems for 
outpatients, not one patient had refused consent to the collection of their 
data.97 The Health Minister said that “reassurance needs to be given to 
provide people with the confidence that the NHS can hold their data and 
that it will be used appropriately”.98
79. Healthcare data and digital technologies provide an opportunity for the 
NHS to improve the adoption of innovations that can lead to improvements 
in patient outcomes as well as cost savings. For example, health monitoring 
apps could reduce hospital admissions by leading to earlier interventions by 
GPs or pharmacists. To take advantage of these opportunities, the NHS 
needs the right structures and must learn from experience.
80. Dame Julie Moore told us that when University Hospitals Birmingham 
NHS Foundation Trust started using video-conferencing for outpatient 
appointments “we were told, ‘The patient has not turned up and we [the 
commissioners] are not paying for it’”. Consequently, in the first year after 
the Trust introduced virtual outpatient appointments it lost £400,000.99 
While this had since been corrected with a new digital tariff, it illustrates 
how existing structures can inhibit the uptake of innovations.
92 Q 44 (Prof Bryan Williams)
93 Q 99 (Prof Keith McNeil)
94 Q 278 (Lord O’Shaughnessy)
95 Q 99 (Prof Keith McNeil)
96 Written evidence from Royal Academy of Engineering (LSI0096)
97 Q 44 (Dame Julie Moore)
98 Q 279 (Lord O’Shaughnessy)
99 Q 44 (Dame Julie Moore)
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81. Sir John Bell told us that “when NHS data is being used there needs to be 
a tangible return to the NHS”. He feared a large US tech company would 
use NHS data to develop algorithms that it then sold from the US, without 
paying tax in the UK or employing anyone in the UK. He said he had asked 
the DHSC to think about how it wants to manage that risk.100
82. The problems standing in the way of exploitation of NHS healthcare 
data for the benefit of patients and the wider economy were explained 
to us by many witnesses. We did not, however, receive commensurate 
evidence about the possible solutions to them. This is probably in part 
because the focus of our inquiry was on the Life Sciences Industrial 
Strategy rather than the NHS. The Government has set out some 
early, welcome steps in the Life Sciences Sector Deal, including the 
establishment of Digital Innovation Hubs which we hope will go some 
way to tackling this.
83. We recommend that the Government should develop solutions to the 
following problems associated with exploiting NHS patient data:
• collection of data in a usable, standardised format across the 
NHS;
• the ability to link different systems across the NHS;
• access to NHS data by third parties and rules for commercial 
exploitation; and the
• public acceptance of and trust in the use of healthcare data for 
patient benefit and research.
These solutions might include financial incentives for Trusts, a 
role for AHSNs in setting up Digital Innovation Hubs as described 
in the Life Sciences Sector Deal, a sustained and substantial public 
engagement campaign and the involvement of the proposed Centre 
for Data Ethics and Innovation.
HARP
84. The Bell report places emphasis on the formation of the Health Advanced 
Research Programme (HARP). The report described HARP as:
“Aimed at encouraging industry to take on bold, far-sighted ambitions 
in the life sciences to potentially create whole new industries based in the 
UK. The intention should be to create commercial success by leading 
and developing new industrial sectors underpinned by novel technology 
and higher risk science.”101
85. HARP programmes would have multiple partners and funders. The Bell 
report defined HARP by reference to the Defence Advanced Research 
Projects Agency (DARPA) in the United States.102 The principle of HARP 
100 Q 218 (Sir John Bell)
101 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 14 
102 The Defence Advanced Research Projects Agency (DARPA) is an agency of the United States 
Department of Defence responsible for the development of emerging technologies for use by the 
military.
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has broadly been welcomed, including by the Government.103 However, there 
is a lack of detail about how it might operate or be funded. The Government 
has said that further proposals on HARP will be made in later phases of the 
Life Sciences Sector Deal.
86. Concerns were raised about HARP. Sir Paul Nurse considered it was a good 
thing but difficult to deliver well.104 Sir Robert Lechler said it was unclear 
where funding for HARP would come from: “what remains to be clarified 
is whether HARP is just folded into the Industrial Strategy Challenge Fund 
… whether there is a pot of money yet to be identified that will fund life 
sciences-type challenges”.105
87. While we welcome the ambition that lies behind the HARP proposal, 
we find the analogy to DARPA in the USA misleading. HARP will not 
have the scale or context of DARPA and should be conceived around 
the opportunities and needs of the UK. The Government must also 
clarify the sources and scale of funding for HARP.
103 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal, p 10
104 Q 67 (Sir Paul Nurse)
105 Q 55 (Sir Robert Lechler)
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CHAPTER 4: FINANCE AND COMMERCIALISATION
88. In its Industrial Strategy Green Paper, the Government stated that Sir John 
Bell had “offered to lead work on a new strategy to make the UK the best 
place in the world to invest in life sciences”.106 His strategy included the 
following strategic goals:
• Create four UK companies valued at greater than £20 billion market 
cap in the next 10 years; and
• Attract 10 large (£50–250m capital investment) and 10 smaller (£10–
50m capital) investments in life science manufacturing facilities in the 
next five years.107
89. In the Life Sciences Sector Deal, the first of the Government’s policies was 
to “Raise total research and development investment to 2.4% of GDP by 
2027”.108 This repeats a commitment in the Conservative Party manifesto 
before the 2017 general election.
UK success at innovation
90. We heard from business, investors and academics that the UK performs 
well in translating basic science into innovation through university spin-outs 
and other early-stage businesses. Professor James Stirling CBE, Provost of 
Imperial College London, said, “if you look at the research volume required 
to generate one spin-out company or to generate a patent and you compare the 
numbers, you find that, in fact, the UK and the US are entirely comparable”.109 
Professor Philip Nelson, Chair of Research Councils UK, praised the UK’s 
strong and internationally competitive science base.110 Sir John Bell pointed 
out that the UK has more small biotech firms than anywhere else in Europe.111
91. The UK was highly praised as a location for business-university collaboration. 
The ease with which businesses can collaborate with universities in the UK 
acts as a magnet for research and development investment by business. Dr 
David Hughes, Head of Global R&D Technology Scouting at Syngenta, said 
that Syngenta had, “over 500 R&D collaborations with external partners 
globally, but over 30% of those are in the UK. It is by far the single most 
important country for collaborative research”.112 The ability of research 
universities in the UK to attract global R&D investors to this 
country should make a significant contribution to the Government’s 
commitment to raise R&D investment to 2.4% of GDP by 2027. It is 
a further reason—if one is needed—to support the very best basic 
science in the UK.
92. Notwithstanding this, we were told that there were significant issues that 
need to be addressed around support for early-stage companies in this sector. 
Kings College London called for, “Innovate UK [to] do more to support 
university spin-out companies”.113 MedCity termed the provision of early-
stage funding for spin outs from higher education “patchy”.114
106 Department for Business, Energy & Industrial Strategy, Building our Industrial Strategy
107 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector
108 Department for Business, Energy & Industrial Strategy and Office for Life Sciences, Life Sciences 
Sector Deal
109 Q 9 (Prof James Stirling CBE)
110 Q 21 (Prof Philip Nelson)
111 Q 198 (Sir John Bell)
112 Q 114 (Dr David Hughes)
113 Written evidence from Kings College London (LSI0070)
114 Written evidence from MedCity (LSI0032)
26 LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
93. We also heard that citations and publishing papers were over-used as 
measures of researchers’ success. Dr Simon Boulton, a Senior Group Leader 
at the Francis Crick Institute, told us:
“We [academics] are judged based on our productivity, where we publish 
our work … There might be strategies that provide an alternative measure 
of somebody’s achievements, for example through the kind of work that 
we do in our laboratories, in terms of discoveries that we publish.”115
Professor Joyce Tait, representing the Royal Society of Edinburgh, told us 
that approaches to evaluating impact as well as citations are needed and 
this is done to a limited extent through the Research Excellence Framework 
(REF). Professor Tait went on to say that the REF could be further improved 
if it “evaluate[s] the research of some academics purely on an impact basis, 
not necessarily on their contribution to highly-rated refereed journals”.116 We 
welcome the growing emphasis on impact in the REF.
Difficulty in growing companies
94. We received consistent and persuasive evidence that the UK is less successful 
in growing small and medium-sized firms into much larger companies. On 
several occasions, overseas investors have acquired growing UK firms as 
they become medium sized. The Bell report contains a goal to develop four 
companies within the sector with a market capitalisation in excess of £20 
billion in the next 10 years.
95. However, as Dr Michael Hopkins and Dr Geoffrey Owen showed, the UK 
has generated only one such firm since 1980.117 Dr Hopkins explained that:
“In the US only 10 companies of that size have emerged since the mid-
1970s and its sector is currently 10 times larger than the UK, in term of 
the public companies. … Of course, a decade is a long time. It is possible 
that the pound could devalue to some extent … It is also conceivable 
that large pharmaceutical companies, such as AstraZeneca or GSK, 
could spin out large businesses, but it is certainly a very ambitious target 
as it stands.”118
The USA, on the other hand, is highly successful in growing highly-
capitalised biotech firms. Sir John Bell told us that whilst he was optimistic 
that the UK could reach the four firms target, “if we got two or three I would 
be happy”.119
96. Without endorsing the specific targets that the Bell report sets, 
we agree that the UK’s historic poor performance in this area is a 
concern because real economic value comes not from funding start-
ups but from enabling scale-up.
115 Q 72 (Dr Simon Boulton)
116 Q 58 (Prof Joyce Tait)
117 Geoffrey Owen and Michael M Hopkins, Science, the State and the City: Britain’s struggle to succeed in 
biotechnology (Oxford: OUP, 2016)
118 Q 175 (Dr Michael Hopkins)
119 Q 233 (Sir John Bell)
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Why is the UK poor at growing companies?
97. We were told that the biggest barrier to growing life sciences firms in the UK 
was the comparative lack of long-term investment or “patient” capital. This 
is a problem for the life sciences sector because of the long maturation time 
for many life sciences technologies.
98. Mike Thompson, Chief Executive Officer of the ABPI, told us:
“Growing into a reasonable-sized pharmaceutical company is expected 
to take up to 20 years. Most venture capitalists want to cash out in six to 
eight years. There has been a gap in the funding available to have that 
long-term investment.”120
Babraham Research Campus said, “patient capital is essential if true 
commercial benefit is to be gained from scientific discoveries”.121 MedCity 
told us, “the gap between [supply and demand] of long-term, patient capital 
is also a major limiting factor for innovative companies in Europe and 
particularly the UK”.122
99. The situation in the USA is different. Dr Andrew Elder, a Partner at 
Albion Capital, told us, “On average, the US funds on the venture end of 
the spectrum are larger and continue to hold and follow their companies 
through more rounds than their UK counterparts”.123 Dr Hopkins said that 
US companies can attract larger amounts of money. This means that:
“Those companies, when they are well-capitalised, have many options. 
They can buy up other companies if their own projects run into problems. 
They can proceed swiftly with their research and development rather 
than having to look continuously for new funding.”124
100. We sought to find out why UK life sciences firms encountered difficulties in 
accessing finance to enable them to grow.
101. A number of witnesses pointed to a lack of specialist investors within the UK 
who understood the life sciences sector. The BIA wrote:
“Technology sectors need investors who understand what they 
are investing in and have the business skills to support a company 
throughout its growth … Increasing the pool of specialist investors 
would help increase the capital flow into the sector and support long-
term sustainable growth.”125
102. Sir Paul Nurse agreed that the UK lacked individuals who understood both 
science and finance. He said the situation was better in the USA where “I 
found there were real experts who understood the territory, who were in the 
investment industry and who had very close contact with academics … We 
need more of that”.126
120 Q 51 (Mike Thompson)
121 Written evidence from Babraham Research Campus (LSI0086)
122 Written evidence from MedCity (LSI0032)
123 Q 127 (Dr Andrew Elder)
124 Q 175 (Dr Michael Hopkins)
125 Written evidence from the BioIndustry Association (BIA) (LSI0017)
126 Q 62 (Sir Paul Nurse)
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Improving access to funds for life sciences companies
103. In this section we consider suggestions made to improve the access of life 
sciences companies to funds to enable them to grow.
Patient Capital Review
104. In November 2016 the Prime Minister announced that HM Treasury would 
carry out a ‘Patient Capital Review’ to “strengthen the UK as a place where 
high-growth innovative firms can obtain the long-term ‘patient’ finance 
that they need to scale up”. An independent panel of industry experts was 
convened by Sir Damian Buffini to support the review. The report of the 
independent panel was published in November 2017.127
105. The evidence we received prior to the publication of the Patient Capital 
Review expressed hope that it would represent a significant step forward in 
addressing the lack of capital flowing to Small and Medium Sized Enterprises 
(SMEs) in the UK life sciences sector.128
106. In August 2017, as part of the review, HM Treasury launched a consultation 
‘Financing growth in innovative firms’. The response to this consultation, 
which also responds to the recommendations of the independent panel, was 
published alongside the Budget on 22 November 2017.129 A summary of the 
Government’s response is in Box 2.
Box 2: Summary of proposed Government actions in response to the 
consultation ‘Financing Growth in Innovative Firms’
Government’s action plan to unlock over £20 billion to finance growth in 
innovative firms over 10 years by:
• Establishing a new £2.5 billion Investment Fund incubated in the British 
Business Bank;
• Significantly expanding the support that innovative knowledge-intensive 
companies can receive through the Enterprise Investment Scheme and 
Venture Capital Trusts;
• Investing in a series of private sector fund of funds of scale;
• Backing first-time and emerging fund managers through the British 
Business Bank’s established Enterprise Capital Fund programme;
• Backing overseas investment in UK venture capital through the Department 
for International Trade;
• Launching a National Security Strategic Investment Fund of up to £85m.
127 Patient Capital Review Industry Panel, Industry Panel Response (22 November 2017): https://www.
gov.uk/government/uploads/system/uploads/attachment_data/file/661397/PCR_Industry_panel_
response.pdf [accessed 22 March 2018]
128 Written evidence from the Academy of Medical Sciences (LSI0107), University College London 
(LSI0058), ABPI (LSI0102), BIA (LSI0017), Q 58 (Sir Robert Lechler) and Q 129 (Dr Andrew 
Elder)
129 HM Treasury, Financing growth in innovative firms: consultation response (22 November 2017): https://
www.gov.uk/government/uploads/system/uploads/attachment_data/file/661398/Patient_Capital_
Review_Consultation_response_web.pdf [accessed 23 March 2018]
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To support long-term investment:
• The Pensions Regulator will clarify guidance on how trustees can include 
investment in assets with long-term investment horizons, such as venture 
capital, infrastructure and other illiquid assets in a diverse portfolio. HM 
Treasury will establish a working group of institutional investors and 
fund managers to increase the supply of patient capital, including tackling 
continuing barriers holding back Defined Contribution pension savers 
from investing in illiquid assets.
• The Government will change the qualifying rules in Entrepreneurs’ Relief 
to remove the disincentive to accept external investment and consulting on 
the detailed implementation of that change.
• The Government will carry out a feasibility study on a new guarantee 
programme modelled on the US ‘Small Business Investment Company’ 
programme.
Source: HM Treasury, Financing growth in innovative firms: consultation response (22 November 2017): https://
www.gov.uk/government/uploads/system/uploads/attachment_data/file/661398/Patient_Capital_Review_
Consultation_response_web.pdf [accessed 23 March 2018]
107. The Government has responded positively to the Patient Capital 
Review and the subsequent consultation and its published action 
plan is a welcome contribution to raising R&D investment in the UK 
and creating the climate and the financial wherewithal for business 
growth.
108. In response to the recommendations of the Review, HM Treasury said it 
planned to establish a working group of institutional investors and fund 
managers. They would examine how to increase the supply of patient capital, 
including by “tackling continuing barriers holding back defined contribution 
pension savers from investing in illiquid assets”.130 The Pension Regulator 
would also issue guidance on how trustees can include investment in assets 
with long-term investment horizons, such as venture capital, infrastructure 
and other illiquid assets in a diverse portfolio.
109. We heard that current rules which inhibit the trustees and managers of 
pension funds in the UK from investing a proportion of their assets in 
higher risk ventures—even when the investment horizon of such funds is 
20–30 years—are a barrier to the flow of capital to innovative firms. Sir 
John Bell told us that the pensions industry itself was frustrated at being 
“limited to gilts and really low-return vehicles”.131 When the USA changed 
the ‘prudent man rule’132 in 1974, “a flood of venture capital into this sector 
occurred”.133 Dr John Bowler, portfolio manager for the Schroder global 
healthcare fund, agreed that this was an area where reform was needed.134
130 ‘‘Patient capital’ plan could unlock pensions savings limits’, Financial Times (24 November 2017): 
https://www.ft.com/content/0c48f8f6-d048-11e7-9dbb-291a884dd8c6 [accessed 22 March 2018]
131 Q 231 (Sir John Bell)
132 Under the Prudent Man Rule, when the governing trust instrument is silent concerning the types of 
investments permitted, the fiduciary is required to invest trust assets as a “prudent man” would invest 
his own property.
133 Q 198 (Sir John Bell)
134 Q 134 (Dr John Bowler)
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110. With over £2tn in UK pension funds, even small changes in investment 
patterns have the potential to transform the supply of capital into innovative 
companies. For example, if, over time, 5% of the £2tn pension pot was 
allocated to the long-term growth of knowledge-intensive firms and if these 
firms put 5% of that investment into UK research, then 0.25% of the pension 
pot—a further £5bn—would be added to UK business R&D.135
111. On the basis of the evidence we have received relating to the Patient 
Capital Review, relaxation of the rules on the allocation of pension 
fund assets to invest in patient capital projects could transform the 
availability of capital to the UK life sciences industry.
112. HM Treasury’s continuing engagement in the implementation and 
further development of the Industrial Strategy in general and its 
implications for the Life Sciences Industrial Strategy will be critical. 
This engagement will include not only promoting the availability of 
funds but also the establishment of a competitive fiscal environment. 
We recommend that the Treasury should report regularly to 
Parliament on progress.
113. We further conclude that the implementation of HM Treasury’s 
response to the Patient Capital Review and the implementation of the 
Sector Deals, particularly in Life Sciences, needs to be co-ordinated 
to be effective. This might be achieved by the Patient Capital 
Review implementation team being represented on the Life Sciences 
Governing Body (see paragraph 49).
114. The implementation of the Life Sciences Industrial Strategy and 
the Government’s commitment to raise R&D investment to 2.4% 
of GDP by 2027 are closely intertwined. We recommend that the 
Government consults widely in the life sciences and other sectors 
before publishing plans to implement the 2.4% commitment and 
that the delivery plan for R&D investment is coordinated with the 
implementation plan for the Life Sciences Industrial Strategy.
Tax environment
115. The tax system can be used to encourage investment in particular areas of 
the economy.
116. We heard praise for some aspects of the UK’s tax environment. The ABPI 
pointed out that the UK’s corporation tax rate is the lowest in the G20.136 
Steve Bates OBE, Chief Executive Officer of the BIA, told us, “the [UK] 
tax environment is very positive and creditable compared to other countries, 
particularly in R&D tax credits”.137
117. The Seed Enterprise Investment Scheme (SEIS) and the Enterprise 
Investment Scheme (EIS) are venture capital schemes run by Her Majesty’s 
Revenue and Customs. They aim to encourage investors to finance companies 
which they may otherwise view as too risky by offering tax breaks.
135 ‘The government has promised more R&D. Where will the money come from?’, The Guardian (4 
January 2018): https://www.theguardian.com/science/political-science/2018/jan/04/the-government-
has-promised-more-rd-where-will-the-money-come-from [accessed 13 April 2018]
136 Written evidence from the ABPI (LSI0102)
137 Q 51 (Steve Bates)
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118. Dr Mark Hammond, co-founder of Deep Science Ventures, said SEIS had, 
“expanded what can be done in terms of the tech-based businesses”138 but it 
did not translate to life sciences or hybrid science-based businesses because 
“the average angel …. They do not have the expertise on a specific life science 
sector. So they just avoid that altogether”.139
119. However, some witnesses said that other aspects of the UK tax environment 
were not attractive to investors. The ABPI told us:
“The UK only has a mid-table ranking in terms of Capital Allowances 
for investment in equipment, making it relatively less attractive to invest 
in pilot and full-scale manufacturing facilities in comparison to other 
countries.”140
120. The BIA argued:
“The inherent flaw in EIS and VCT [Venture Capital Trusts] schemes 
is that investors cannot follow their money in future non-qualifying 
fundraises. This penalises early investors as they become diluted as a 
company progresses.”141
They suggested that continued tax relief for EIS and VCT investors when 
investing further in companies they have backed at an early stage and 
preferential access to further fundraises would, “incentivise greater and 
longer-term investing”.142
121. The Government has placed a strong emphasis, both in the Industrial Strategy 
and in the Life Sciences Sector Deal, on raising total R&D investment in the 
UK to 2.4% of GDP by 2027. Much of the increase will come from business 
investment. Around half of the UK’s existing business investment in R&D 
comes from companies headquartered overseas and there is potential to 
further increase foreign direct investment in R&D as a contribution to the 
2.4% target through tax incentives.
122. The APG recommended that the Government should introduce measures to 
increase investment in R&D as part of a holistic approach to building a strong 
life sciences ecosystem which enables swift identification, access and uptake 
of innovative new medicines. They told us that, “this approach should also 
include measures to improve fiscal incentives for private sector investment in 
R&D, with the focus in the LSIS on incentives for manufacturing, tax and 
start-ups”.143
123. We welcome the Government’s commitment to raising R&D 
investment in the UK to 2.4% of GDP by 2027and the emphasis it has 
been given. We look forward to the Government’s plan for delivering 
the increase.
138 Q 128 (Dr Mark Hammond)
139 Ibid.
140 Written evidence from the ABPI (LSI0102)
141 Written evidence from the BIA (LSI0017)
142 Ibid.
143 Written evidence from the American Pharmaceutical Group (APG) (LSI0110)
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124. We recommend that the Government should review ways to increase 
further the attractiveness of the UK as a location for business 
investment in R&D, not least in the life sciences. We recommend that 
the review should include benchmarking of UK tax incentives against 
those in other research-intensive nations. We also recommend that 
the review should develop proposals for close cooperation between 
UK Research and Innovation, the Department for International 
Trade and the Department for Business, Energy and Industrial 
Strategy in attracting higher levels of foreign direct investment in 
R&D.
Convergent training
125. A number of witnesses suggested that greater availability of convergent 
training—where individuals were knowledgeable about or had qualifications 
in both science and business—would aid the flow of capital to innovative UK 
firms. Firms in the UK will be at a disadvantage if their overseas competitors 
have better access to people with convergent skills.
126. Professor Chris Lowe OBE, Director of the Cambridge Academy of 
Therapeutic Sciences at the University of Cambridge, emphasised the 
importance of entrepreneurship, “if you are going to generate a lot of new 
ideas which will eventually feed through to a large multinational industry, 
you need the entrepreneurs to set that up and get it running. It is a matter of 
culture”.144
127. Bristol BioDesign Institute told us that “entrepreneurship training” was a 
skills gap within the life sciences sector.145 Sir John Bell told us, “the US has 
been very good at convergent training, in a sense, where people will get a 
science degree, then get an MBA, then go out into industry”.146 His strategy 
stated:
“There should be support for entrepreneur training at all levels, 
incentivising varied careers and migration of academic scientists into 
industry and back to academia to increase influx of talented scientists 
and entrepreneurs in the public and private sectors.”147
128. Birmingham Health Partners similarly suggested that:
“Better and more relevant postgraduate training and courses are required 
alongside greater training through other education routes to develop a 
broad workforce that spans discovery science to adoption. … Training 
needs to cover a broad range of skills including commercial skills.”148
129. The British Society for Immunology recommended that more opportunities 
for training in business development skills should be offered, which would take 
academics “out of their comfort zones and … instil a more entrepreneurial 
mind-set. Indeed, these opportunities could be integrated into undergraduate 
degree programmes to help blend commercial acumen into the training of 
the next generation of scientists”.149 Professor Tony Young, National Clinical 
144 Q 10 (Prof Chris Lowe OBE)
145 Written evidence from the Bristol BioDesign Institute (LSI0027)
146 Q 232 (Sir John Bell)
147 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 64
148 Written evidence from Birmingham Health Partners (LSI0034)
149 Written evidence from the British Society for Immunology (LSI0072)
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Director, Innovation at NHS England, told us that the UK had “the world’s 
largest entrepreneurial training programme for clinicians from the National 
Health Service”.150
130. Two representatives of SMEs from the life sciences sector who gave oral 
evidence to us did not agree that there was a gap between scientists and 
financial experts in the UK. Ian Staples, Chief Executive of Matoke Holdings 
Ltd said there was no gap at SME level and he and Mr Campbell agreed that 
part of their role was to bring people with those skills together.151
131. We recommend that the Government should review both the 
opportunities for training scientists and clinicians in business and 
entrepreneurial skills, and for encouraging members of the financial 
sector to develop sufficient understanding of the basics of the science 
and technology in which they are investing their clients’ money.
150 Q 289 (Prof Tony Young)
151 Q 29 (Mark Campbell CBE, Ian Staples)
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CHAPTER 5: SKILLS AND TRAINING
132. We were told repeatedly that the Life Sciences Industrial Strategy needs 
to be a long-term endeavour. We heard that an essential requirement for 
implementation was a workforce with the skills and agility to seize the 
economic and social opportunities and address the challenges in propelling 
the UK to the world-leading position envisaged by the Bell report and the 
Life Sciences Sector Deal.
133. The Bell report stated, “the ultimate success of the Life Sciences Industrial 
Strategy is closely tied to the ability to train and recruit the best possible 
workforce, equipped with a breadth of critical skills”.152
134. Witnesses praised the emphasis given to skills in the Bell report. Sir Paul 
Nurse said that it recognised “the exceedingly important issue of skills, 
having appropriate skills, and the ability to recruit the very best from around 
the world”.153
Access to international talent and skills
135. Many businesses in the life sciences sector rely on access to talent from 
around the world—from within and outside the EU. The PHG Foundation, 
a health policy think-tank, told us that, “without the capacity to attract 
international experts in the life sciences to live and work in the UK, whether 
in the commercial, third or academic sector, ambitions for a world class life 
sciences industry will inevitably be curtailed”.154
Brexit uncertainty
136. Within the EU, workers benefit from freedom of movement, allowing them 
to reside and work freely in any member state. We heard that freedom of 
movement had “been a great advantage to the life sciences sector”.155 Brexit 
poses a potential barrier to the UK’s access to talent from the EU and to the 
access that UK citizens have to professional development opportunities in 
other member states.
137. Dr Menelas Pangalos, Executive Vice President of Innovative Medicines and 
Early Development (IMED) at AstraZeneca, told us that he was:
“Worried about the impact of Brexit on our employees … the fact that we 
have no idea what is going to happen is a real problem. We are starting 
to see people turn us down now in the UK because they do not know 
what the outcome will be for future employment.”156
Sir Paul Nurse told us that the UK’s “image is suffering terribly at this 
moment”.157 The BEIS Minister agreed that the UK’s image “had suffered 
a bit as a result of Brexit”, but said the UK was still able to “attract the 
people”158 and that they will be welcomed.159
152 Sir John Bell, Life Sciences Industrial Strategy—A report to the Government from the life sciences sector, p 50
153 Q 60 (Sir Paul Nurse)
154 Written evidence from the PHG Foundation (LSI0048)
155 Written evidence from Merck (LSI0118)
156 Q 24 (Dr Menelas Pangalos)
157 Q 66 (Sir Paul Nurse)
158 Q 283 (Lord Henley)
159 Ibid.
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138. Witnesses called for the Government urgently to reassure businesses and 
individuals that the UK would keep its “door open to talent”160 after Brexit. 
Sir Robert Lechler said: “We need, as rapidly as the negotiations will allow, 
to give certainty to our current continental European academics and to those 
we are trying to recruit that they will absolutely be welcome, secure and safe 
and that it will not be more difficult”.161
Access to global talent and immigration reform
139. The life sciences sector requires “unencumbered access to high quality 
talent”.162 Sir Paul Nurse said the current visa system for individuals coming 
to work in the UK from outside the EU was “expensive, tedious and put 
people off”.163 Dave Allen, Senior Vice President, Respiratory Disease R&D 
at GSK, said that it needed to be simple for talented individuals to come to 
work in the UK because otherwise the UK would not be able “to compete 
with countries that are prepared to make it much easier for people to move 
and thrive in those countries”.164 Merck said that it would welcome steps to 
ease “the administrative and cost burden of bringing non-EU workers to the 
UK”.165 Tier 2 visas are issued to skilled non-European workers including 
doctors and other healthcare staff, software developers and laboratory 
scientists. In December 2017, January 2018 and February 2018 the cap for 
tier 2 visas was hit for an “unprecedented”166 three months in a row.
140. Currently, because of mutual recognition of qualifications, medical doctors 
from within the EU are not subject to the lengthy process to practise in the 
UK that medical doctors from the rest of the world must face. Sir John Bell 
said the General Medical Council made it:
“Almost impossible to recruit the most talented, skilled clinician scientists 
from around the world into the UK. The paperwork that people have to 
complete is awesome … They wait years to get approval. If we are going 
into a world where we are on our own [post-Brexit], we had better sort 
that problem out, because it will completely stuff us.”167
141. The BEIS Minister assured us that the Government wanted “to reduce red 
tape in hiring international researchers, members of established research 
teams and so on”168 and that discussions with the Home Office on this issue 
would continue. He pointed out that the Government had already “doubled 
the number of visas that will be available under tier 1, which is for exceptional 
talent”.169 Whilst this is welcome, we heard that there were skills gap at many 
levels in the life sciences sector, not just at the exceptional talent level. We 
discuss this in paragraph 156 below.
160 Written evidence from Merck (LSI0118)
161 Q 59 (Sir Robert Lechler)
162 Written evidence from APG (LSI0110)
163 Q 66 (Sir Paul Nurse)
164 Q 24 (Dave Allen)
165 Written evidence from Merck (LSI0118)
166 ‘UK hits visa cap on skilled workers for third month in row’, The Guardian (18 February 2018): https://
www.theguardian.com/uk-news/2018/feb/18/uk-hits-skilled-worker-visa-cap-third-month-home-
office-refuses-applications [accessed 12 April 2018]
167 Q 236 (Sir John Bell)
168 Q 283 (Lord Henley)
169 Ibid.
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142. The MSC and the AUKUH called for the Government to “adopt a strategy 
that welcomes international talent and facilitates long term settlement in the 
UK for research workers and their families”.170 Alzheimer’s Research UK 
said that Brexit represented an opportunity to produce:
“An immigration system that recognises the collaborative nature 
of science and supports the thriving research and innovation base in 
the UK … The system must be fair, transparent and efficient, and 
sufficiently flexible to allow for the UK’s changing skills needs and 
research priorities in the years ahead.”171
143. Following an earlier recommendation from this Committee172 the 
Government introduced the Rutherford Fund173 for the specific purpose 
of attracting highly talented researchers to the UK from around the world. 
This fund has a low profile in the Life Sciences Industrial Strategy.
144. The Government and UK Research and Innovation should promote 
and expand the Rutherford Fund, aligning its objectives with those 
of the Life Sciences Industrial Strategy where appropriate.
145. Immigration policy is central to the continued success of the UK 
life sciences sector. Any inhibition of free movement arising from 
Brexit will add urgency to the case for reform. The Department for 
Business, Energy and Industrial Strategy should assess what is 
required in the way of scientific talent from overseas and work with 
the Home Office to ensure that immigration regulations can facilitate 
this. Furthermore, we recommend that the body responsible for 
implementing the Life Sciences Industrial Strategy should include 
senior representation from the Home Office so that immigration 
policy can be incorporated into implementation plans.
Skills training in the UK
146. In the previous section we considered access to global talent. In this section 
we consider the evidence about skills gaps within the life sciences sector and 
action required to ensure that the sector has access to home grown talent and 
skills.
Schools
147. We heard that building a home-grown skilled workforce was a long-term 
endeavour that needed to start in primary schools. Medtronic said that 
Science, Technology, Engineering and Mathematics (STEM) subjects 
needed to be prioritised “from the beginning to the end of a pupil’s time in 
education”.174 Imperial College London said the focus on STEM needed to 
begin in primary and secondary education “to increase the proportion of 
the population who go on to be equipped with the advanced skills needed 
170 Written evidence from Medical Schools Council (MSC) and Association of UK University Hospitals 
(AUKUH) (LSI0081)
171 Written evidence from Alzheimer’s Research UK (LSI0024)
172 Science and Technology Committee, A time for boldness: EU membership and UK science after the 
referendum (1st Report, Session 2016–17, HL Paper 85)
173 Department for Business, Energy & Industrial Strategy, Press release: ‘£100 million Rutherford Fund 
to attract best researchers to the UK’, 4 July 2017: https://www.gov.uk/government/news/100-million-
rutherford-fund-to-attract-best-researchers-to-the-uk [accessed on 23 March 2018]
174 Written evidence from Medtronic (LSI0039)
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by industry”.175 Merck said there needed to be a partnership between the 
education system and industry to encourage more young people into careers 
in science.176
148. PHG Foundation pointed out that teachers with skills in STEM were “in 
critically short supply in secondary schools, and even rarer in primary 
schools”.177
Universities
149. Witnesses made a number of suggestions for action that universities could 
take to increase the breadth and depth of the skills of life sciences students 
and researchers.
150. We heard that there were skills gaps in many areas relating to the life sciences 
sector including data science,178 engineers qualified in good manufacturing 
practice,179 computational science, data management, toxicology and 
pathology, oncology, translational science, epidemiology, health economics 
and genomics.180
151. In Chapter 4 we discussed the need for convergent training, whereby 
individuals understand both science and business. This should improve 
mutual understanding between the scientific and investment communities 
with a view to increasing the flow of capital into the sector. Dr Peter Hughes 
Healthcare Equity Analyst at AXA Framlington Biotech Fund, explained 
that the situation was different in the USA, where:
“When we see initial public offerings or follow-on offerings coming 
to market … they are generally … undertaken by specialist investors, 
whereas in the UK quite often we will see generalist investors … there 
is a difference in the level of investor understanding and sophistication 
with regards to specific life sciences offering.”181
152. In a similar vein we were told that universities should offer wider training 
in business, investment and entrepreneurship to undergraduates and those 
pursuing further research in the life sciences.
153. Loughborough University said universities had a responsibility to produce 
highly technically skilled individuals and to:
“Develop their entrepreneurial abilities, train and guide [them] 
to consider intellectual property, understand financial models for 
commercialisation and interdisciplinary working as part of their holistic 
development.”182
The Academy of Medical Sciences similarly noted that the academic sector 
would benefit from additional skills in “business, entrepreneurialism and 
management”.183
175 Written evidence from Imperial College London (LSI0112)
176 Written evidence from Merck (LSI0118)
177 Written evidence from PHG Foundation (LSI0048)
178 Q 18 (Prof Philip Nelson)
179 Written evidence from the ABHI (LSI0091)
180 Written evidence from AstraZeneca (LSI0117)
181 Q 127 (Dr Peter Hughes)
182 Written evidence from Loughborough University (LSI0033)
183 Written evidence from the Academy of Medical Sciences (LSI0107)
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154. Professor John Atherton, Pro Vice-Chancellor and Dean of the Faculty of 
Medicine and Health Sciences at the University of Nottingham, acknowledged 
that the provision of such skills to medical school students had traditionally 
not been well-developed but universities were now concentrating on this area: 
“increasingly, in the taught part of PhD training programmes … innovation 
skills are being brought in and that is now finding its way, slightly slowly 
perhaps, into clinical academic training as well”. 184 Professor Lowe told us 
about a course he had run in bioscience enterprise which equipped medical 
students with the skills needed to establish companies.185
155. Witnesses from industry told us that graduates often lacked the hands-on 
skill and experience of a laboratory environment. Merck called for a greater 
focus on the way in which “students’ learning in the classroom relates to a 
career in science and technology”.186
Technicians and apprenticeships
156. The UK’s requirement for skilled workers for the life sciences sector is not 
limited to graduates or senior scientists. We heard that there was an urgent 
need for more technicians and apprentices in this sector.
157. On technical training, the Bell report recommends:
“The Government should establish Institutes of Technology that would 
provide opportunity for technical training, particularly in digital and 
advanced manufacturing areas.”187
158. On apprenticeships the Bell report recommends that the Government should:
“Create an apprenticeship scheme that focuses on data sciences, as well 
as skills across the life sciences sector, and train an entirely new cadre 
of technologists, healthcare workers and scientists at the cutting-edge of 
digital health.”188
159. Dr Paul Lewis, King’s College London, said that employers believed that 
specialist manufacturing and laboratory technician roles are “best filled by 
specialist technicians (rather than by graduates)”.189 He said that the use 
of over-qualified, but under-skilled, graduates to fill technician roles was 
“problematic, both because graduates lack practical skills and also because 
they become dissatisfied with the work and pay associated with technician 
roles”.190
160. The Royal Microscopical Society commented that funding technician level 
apprenticeships was a good aim but needed expanding and:
“Careful thinking about a career path for these technicians is needed 
(for example, in universities, the numbers of technical support staff have 
been decreasing over the past 20 years), and if there are enough available 
formal training courses for them.”191
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161. The Royal Society of Biology recommended that technical education should 
be promoted and developed to provide:
“Alternative routes to develop skills in the life sciences sector, including 
apprenticeships … which may provide alternative routes for people to 
enter higher education. Recognition and support for those following 
technical routes is important to encourage retention of individuals 
following this track.”192
The Royal Society of Chemistry called for quality vocational education 
and apprenticeships across the life sciences sector.193 The ABPI said that 
there needed to be greater flexibility associated with the development of new 
apprenticeship standards and employment of apprentices.194
162. The BEIS Minister said that the Government was aware of the need for 
action:
“That is why in the Life Sciences Industrial Strategy we looked at a 
group of six recommendations on developing a reinforced skills action 
plan, creating a new apprenticeship scheme, focusing on data sciences 
and establishing Institutes of Technology that will provide opportunities 
for technical training and support for entrepreneur training at all levels. 
These all come straight from the Life Sciences Sector Deal and are 
what the Government should be pursuing: a fund being established to 
support convergent science activities and high-quality STEM education 
being provided for all.”195
Conclusion and recommendations on a skilled workforce
163. We welcome Sir John Bell’s recommendations on the need to deliver 
a skilled workforce for the life sciences sector. However, without a 
clear implementation plan the chances of action in this area, which 
requires cross-departmental coordination, seem slim. Progress will 
require the full cooperation of and support from the Department for 
Education. We therefore recommend that the membership of the Life 
Sciences Governing Body should include a senior representative 
from the Department for Education.
164. While further education has an important role in developing the 
full range of skills, the further education sector has had a low 
profile in the Life Science Industrial Strategy and in ministerial 
announcements on the Industrial Strategy more widely. We welcome 
the Government’s announcement of the establishment of new 
Institutes for Technology. Closer integration of further and higher 
education in the implementation of the Life Sciences Industrial 
Strategy would be welcome. We recommend that the Department 
for Business, Energy and Industrial Strategy and the Department 
for Education publish a joint statement on the relationship between 
higher and further education in the implementation of the strategy.
192 Written evidence from the Royal Society of Biology (LSI0101)
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165. Incremental development and strengthening of further education 
will not provide the boost needed to address the skills challenges 
identified in evidence to this inquiry. We recommend that the 
Department for Education promote stronger and more varied 
relationships between the further education sector and the business 
community, for example by creating the further education equivalent 
of the widely praised Higher Education Innovation Fund that has 
done so much to enhance university-business relationships over the 
last decade.
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CHAPTER 6: SCIENTIFIC EXCELLENCE
166. Many witnesses highlighted the importance of maintaining the UK’s 
excellent science base as part of the Life Sciences Industrial Strategy, not 
least because it attracted global corporations to invest in the UK. In this 
Chapter we make recommendations on how to maintain excellence in UK 
science.
Basic Science
167. The Government’s Industrial Strategy provided a welcome emphasis on 
the economic value of high-quality scientific research. The actions arising 
from the strategy will focus on economic development. However, any long-
term strategic view of the economy should protect and nurture science at the 
frontiers of knowledge—sometimes referred to as ‘discovery science’.
168. The BIA told us that “maintaining the UK’s world-leading science base … is 
essential to the UK’s long-term attractiveness for life sciences investment”.196 
A similar point was made by other witnesses.197
169. The Government has committed to increase investment in R&D to 2.4% of 
GDP by 2027 and to 3% in the longer term. Much of the immediate public-
sector contribution to increased R&D investment (up to 2020/21) is through 
the Industrial Strategy Challenge Fund (ISCF). The focus of the ISCF is 
mainly on applied research and innovation within specific ‘challenges’ that 
have been identified by the Government. While this increase in funding is 
welcome, Sir Robert Lechler told us that in order to maintain the excellence 
of the UK science base it is important to maintain a balance between research 
funding for discovery and applied science. He saw “a risk that discovery 
science may be disadvantaged if we are not careful in the current climate”.198
170. AstraZeneca told us that the 2.4% target was lower and would be achieved 
more slowly than the sector would like to see.199 This point was echoed by Dr 
Mark Downs, Chief Executive of the Royal Society of Biology.200 The Bell 
report calls for the UK to be in the top quartile of OECD countries on R&D 
spending, which would equate to 2.6% of GDP.201
UK Research and Innovation
171. UK Research and Innovation (UKRI) came into existence in April 2018 
and has an important role to play in the implementation of the Life Sciences 
Industrial Strategy and the Industrial Strategy more widely. UKRI brings the 
seven research councils, the research arm of the Higher Education Funding 
Council for England (HEFCE) and Innovate UK under the umbrella of one 
public body. That will, in principle, allow better co-ordination of resources 
and provide a single voice to Government for science and innovation.
196 Written evidence from the BIA (LSI0017)
197 Written evidence from Lilly UK (LSI0106), Q 22 (Dave Allen) and Q 188 (Louise Houson)
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172. The creation of UKRI opens further opportunities to fund research and 
innovation programmes that combine established fields of life sciences with, 
for example, mathematics, engineering and social sciences. Professor Paul 
Kellam from the Microbiology Society told us that:
“It is the cross-fertilisation between disciplines within the biomedical 
arena that leads to innovation … this is a coming together of three or 
four strands of technology, from computer science, genomics, infectious 
disease and ecology.”202
173. The White Paper says that the Government will work with UKRI to develop 
a new competitive ‘Strategic Priorities Fund’, which builds on the vision of a 
common fund as set out in Sir Paul Nurse’s review of research councils.203 The 
White Paper states that this fund “will support high quality R&D priorities 
which would otherwise be missed—multidisciplinary and inter-disciplinary 
programmes identified by researchers and businesses at the cutting edge of 
research and innovation”.204 Professor Sir Mark Walport, chief executive of 
UKRI, told us that:
“Part of our job in UK Research and Innovation is to catalyse the 
research and innovation community to answer the sorts of questions 
that might not be answered simply by a programme grant or a fellowship 
programme. It is about how we stimulate the imagination of the 
community to come up with the big and important questions.”205
Place
174. The White paper contains five “foundations of productivity” one of which is 
“places—to have prosperous communities across the UK”. The White Paper 
says that the UK has greater disparities in regional productivity than other 
European countries.206 We heard a range of views on the distribution of the 
life sciences sector and the availability of investment and public funding 
across the UK.
175. Sir John Bell told us that there is “a very dense aggregation of the high-
tech sector in the south east, co-located with the major universities”, often 
called the ‘golden triangle’, with Oxford, Cambridge and London as its 
three corners. However, as he looked around the country he “became much 
more relaxed that we did not, in life sciences, have this issue of place”.207 He 
thought that the sector looked different in different parts of the country 
and, therefore, the whole country is never going to look like the golden 
triangle. The BEIS Minister told us that he did not think there was an over-
concentration of the sector in the south east.208 The Health Minister said 
“22% [of the sector] is in the south-east of England but 21% is in the north 
of England”.209
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176. Others were concerned that there was too much focus on the golden triangle. 
The University of Nottingham told us that “geographic distribution of life 
science investment in the UK is a particular issue. Research infrastructure is 
good in the Golden Triangle but as a country we need to ensure all regions 
have access to funding and facilities”.210 Queens University Belfast told us that 
“access to investment funding is sub-optimum, especially outside the ‘golden 
triangle’. This is a particular issue for devolved regions such as Northern 
Ireland”.211 The Life Sciences Scotland Industry Leadership Group told us 
that “investment for life sciences is seen as high risk and available funding in 
the UK is centred around the golden triangle in the south-east”.212
177. Louise Houson, UK Managing Director of US-based MSD, who recently 
announced a new research centre to be based in London, told us that this 
decision “was based on our ability to get access to the best scientific talent. 
… this is a really good place at the moment to do early discovery-stage 
science … we believe that this is where the best science is”.213 AstraZeneca, 
who have also recently moved a large amount of R&D activity to Cambridge 
from the north-west, said that the UK should “play to our science strengths 
by developing clusters of global excellence in research (such as the golden 
triangle)”.214
178. Increasing investment in the regions of the UK should not be at the 
expense of the golden triangle; the concentration of excellence in 
the south-east attracts private-sector investment. Such investment 
is essential to the Government’s commitment to raise R&D levels to 
2.4% of GDP by 2027.
Clusters
179. The Bell report says that geographical clustering of companies alongside 
their supply chain can bring additional economic benefits. Dr Glenn Crocker 
MBE, representing the UK Science Park Association, told us that this was 
because “they tend to spark off each other and you get collaborations. You get 
lots of communication between them. Then the sector grows and grows”.215 
Professor Stirling said, “one cannot stress too much the importance of the 
geographical co-location of scientists from industry, from academia and 
from the health sector … proximity is so important in this”.216 MedCity, 
themselves a cluster organisation, told us that cluster organisations can “help 
make an impact through their ability to bring their networks together and 
mobilise initiatives”.217
180. The Bell report describes the golden triangle as an example of a cluster. For 
other witnesses clusters are smaller in scope—for example the Cambridge 
life sciences cluster. Clusters are almost always based around a university 
or other research institute. The Bell report states that governments cannot 
create clusters but they can support their growth by providing the necessary 
infrastructure and access to funding for research.218 The Health Minister 
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told us that the Government will not “try to force a specialism on areas 
that do not have one just for the sake of spreading them out, but to try to 
build on expertise that exists”.219 The Foreign and Commonwealth Office 
told us that Germany, at both federal and state level, has strongly supported 
cluster growth in recent years. At a federal level this had been through open 
competition for funding.220
181. Clusters can involve parts of the NHS—for example, large teaching hospitals. 
The Shelford group, which represents 10 English academic healthcare 
organisations, told us that “incentivising leading NHS organisations to work 
together with universities and industry as innovation hubs/clusters” can help 
create “local and national engines of economic growth”.221
182. We recommend that UK Research and Innovation should include 
in its published strategy a commitment to maintaining the UK’s 
position as one of the world top three nations in scientific discovery 
in the life sciences sector.
183. We support the Government’s efforts to improve the geographical 
spread of excellent research throughout the UK. Clusters containing 
universities, teaching hospitals, and companies large and small can 
help drive the success of the life sciences sector. The Government 
should identify clusters of excellence and encourage their growth.
Innovation and Catapults
184. Catapults are designed to “support innovative businesses by providing access 
to the critical facilities and expertise they would not find together elsewhere” 
and to enable “SMEs to access the support needed to bring products and 
services to market for the first time”. There are a number of catapults that 
operate in the life sciences sector: the Cell and Gene Therapy Catapult, the 
High Value Manufacturing Catapult and the recently established Medicines 
Discovery Catapult. Innovate UK is responsible for oversight of the network 
of catapults.
185. The Royal Academy of Engineering told us that Catapults “play an 
important role supporting innovations to bridge the gap from R&D to 
commercialisation”. The Government said that Catapults “play a key role 
in supporting the innovation landscape”.222 However, aside from Catapults 
themselves and Innovate UK, few of our witnesses mentioned Catapults as a 
way of improving the commercialisation of research and growing new spin-
out companies.
186. An independent EY review of catapults was commissioned and published by 
the Government. It found that “the concept of Catapults is sound and, when 
effectively implemented, Catapults have the potential to drive innovation and 
economic benefit to the UK”.223 Dr Ruth McKernan CBE, Chief Executive 
of Innovate UK, told us that Innovate UK will take on board the EY review 
and will make “some changes and modifications”.224 Sir Mark Walport said 
it will be the job of UKRI to implement the findings of the report.225
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187. We recommend that the Government implements in full the 
recommendations of the EY review of Catapults that are relevant to 
the Life Sciences.
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SUMMARY OF CONCLUSIONS AND RECOMMENDATIONS
Challenges of implementation
1. We recommend that the Government should identify and publish the areas 
of life sciences not covered by the Bell report and the Life Sciences Sector 
Deal. Businesses and investors in parts of the life sciences not covered will 
then know the areas in which they are free to propose further sector deals. 
(Paragraph 16)
2. There is some ambiguity about the status of the Bell report and its 
implementation. We recommend that the Government should adopt the Bell 
report in full and provide an implementation plan to which it and the other 
stakeholders can be held to account. (Paragraph 18)
3. The evidence we have heard, particularly about the failings of the 2011 Life 
Sciences Strategy, has highlighted the importance of a detailed implementation 
plan that contains timelines, milestones and metrics for measuring success. 
The Bell report provides the vision for the sector; the Government must now 
work with stakeholders to draw up an implementation plan. (Paragraph 22)
4. The Government remains focused on a transactional relationship with rather 
than a strategic partnership with the life sciences sector. This is inadequate. 
(Paragraph 26)
5. The first phase of the Life Sciences Sector Deal as published does not 
constitute a plan that will ensure the successful implementation of the Bell 
report. The Sector Deal is designed along the lines of those for other sectors. 
It does not take account of the important and central role of the NHS which 
necessitates greater Government involvement in the life sciences sector. 
(Paragraph 30)
6. We are disappointed that the Sector Deal does not contain the metrics, 
governance and oversight arrangements that the Government had promised 
in its written evidence. It lacks operational detail on how different arms of the 
Government will work together towards a single objective. Furthermore, it 
does not provide information about the provision and allocation of resources 
for many strands of implementation (particularly those involving the NHS). 
(Paragraph 31)
7. As a minimum, the Government must clarify urgently:
• Which bodies are responsible for each aspect of operational delivery of 
implementation;
• The membership of these bodies;
• Their terms of reference; and
• The authority these bodies will have to coordinate policy and delivery 
across Government departments.
8. In paragraph 49 we set out our proposals for the implementation of 
the strategy which go beyond the minimum standards set out above. 
(Paragraph 34)
9. The Government should propose and obtain agreement from all stakeholders 
to an implementation plan for the Bell report and the Life Sciences Sector 
Deal, which must be integrated with the implementation of the overall 
Industrial Strategy. (Paragraph 37)
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10. The Government must clarify exactly which documents comprise the 
Life Sciences Industrial Strategy. This is still unclear and successful 
implementation cannot be achieved until it is clarified. Most witnesses 
told us that they understand the strategy to be the Bell report and the Life 
Sciences Sector Deal and we have adopted that definition. (Paragraph 46)
11. Implementation and oversight are vital to the success of both the Life Sciences 
Industrial Strategy and the wider Industrial Strategy. The Government’s 
plans for implementation and oversight do not provide an effective model 
and as set out are a recipe for failure. Not only do they lack clarity and detail, 
they fail adequately to take account of the central role of the NHS in the life 
sciences sector. (Paragraph 47)
12. In the following paragraphs we set out our proposal for delivery, accountability 
and leadership which, drawing on the Government’s model and suggestions 
made to us by witnesses, sets out a clear and effective system for implementing 
the Life Sciences Industrial Strategy. See also Figure 1, which shows our 
proposal in the form of a diagram. (Paragraph 48)
13. The Government’s system for implementation is too complex and duplicative. 
We recommend that, in place of the Life Sciences Implementation Board 
and the Life Sciences Council, there should be a single body (referred to 
hereafter as the Life Sciences Governing Body) responsible for the delivery 
of the Life Sciences Industrial Strategy, which should:
• Be co-chaired by the Secretary of State for Business, Energy and 
Industrial Strategy and the Secretary of State for Health and Social 
Care with executive leadership from Sir John Bell as Life Sciences 
Champion;
• Meet frequently;
• Have a membership of about 12, including senior figures from the 
NHS, industry, academia and the charities sector;
• Take the lead in drawing up an implementation plan, with clear 
milestones, timelines and criteria for success;
• Task subordinate working groups with the actual operational delivery 
of specific areas of the plan; and
• Report to a Cabinet Committee. (Paragraph 49)
14. The Secretaries of State for Business, Energy and Industrial Strategy and 
Health and Social Care should ensure the Life Sciences Governing Body 
has the backing required to do its work and should take responsibility for the 
cross-Government aspects of the strategy. (Paragraph 50)
15. We recommend the creation of a new statutory body, the Office for Industrial 
Strategy (OfIS) with the authority to scrutinise the implementation of the 
wider Industrial Strategy and the Life Sciences Industrial Strategy and to 
publish its findings. The remit of the OfIS should cover the implementation 
of the Patient Capital Review. The OfIS would be accountable to Parliament 
and report annually on progress made by each Government department in 
implementing the Industrial Strategy. (Paragraph 51)
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Role of the NHS
16. The current structure of the NHS stifles innovation. A focus on cost-control 
and a lack of co-ordination between the various bodies that make up the 
NHS means that the adoption and spread of innovations is not given the 
priority it requires. Unless the NHS’s ability to adopt and spread innovations 
is improved, it will not be able to play a full role in the implementation of 
the Life Sciences Industrial Strategy. This will endanger the success of the 
strategy. (Paragraph 61)
17. NHS England and NHS Improvement must give the highest priority to the 
adoption and spread of innovation throughout the NHS. They should work 
together to align their strategies to maximise the chances of success in this 
area. (Paragraph 62)
18. The NHS should give greater priority to the uptake and spread of innovation 
and to rewarding clinicians and managers who make such adoption 
successful. We recommend that the Government should explore how it can 
offer financial incentives to those NHS trusts that adopt and spread proven 
innovations. (Paragraph 71)
19. The Academic Health Science Networks have a role to play in driving the 
adoption at pace and scale of innovations throughout the NHS. Where 
they are working well AHSNs should be further developed. AHSNs should 
have a clear link to the Life Sciences Governing Body (see paragraph 49). 
(Paragraph 72)
20. We recommend that NHS England should mandate the uptake of those 
innovations that have been shown to improve patient outcomes and provide 
good value for money. (Paragraph 73)
21. The problems standing in the way of exploitation of NHS healthcare data for 
the benefit of patients and the wider economy were explained to us by many 
witnesses. We did not, however, receive commensurate evidence about the 
possible solutions to them. This is probably in part because the focus of our 
inquiry was on the Life Sciences Industrial Strategy rather than the NHS. 
The Government has set out some early, welcome steps in the Life Sciences 
Sector Deal, including the establishment of Digital Innovation Hubs which 
we hope will go some way to tackling this. (Paragraph 82)
22. We recommend that the Government should develop solutions to the 
following problems associated with exploiting NHS patient data:
• collection of data in a usable, standardised format across the NHS;
• the ability to link different systems across the NHS;
• access to NHS data by third parties and rules for commercial 
exploitation; and the
• public acceptance of and trust in the use of healthcare data for patient 
benefit and research.
23. These solutions might include financial incentives for Trusts, a role for 
AHSNs in setting up Digital Innovation Hubs as described in the Life 
Sciences Sector Deal, a sustained and substantial public engagement 
campaign and the involvement of the proposed Centre for Data Ethics and 
Innovation. (Paragraph 83)
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24. While we welcome the ambition that lies behind the HARP proposal, we find 
the analogy to DARPA in the USA misleading. HARP will not have the scale 
or context of DARPA and should be conceived around the opportunities and 
needs of the UK. The Government must also clarify the sources and scale of 
funding for HARP. (Paragraph 87)
Finance and commercialisation
25. The ability of research universities in the UK to attract global R&D investors 
to this country should make a significant contribution to the Government’s 
commitment to raise R&D investment to 2.4% of GDP by 2027. It is a 
further reason—if one is needed—to support the very best basic science in 
the UK. (Paragraph 91)
26. Without endorsing the specific targets that the Bell report sets, we agree that 
the UK’s historic poor performance in this area is a concern because real 
economic value comes not from funding start-ups but from enabling scale-
up. (Paragraph 96)
27. The Government has responded positively to the Patient Capital Review 
and the subsequent consultation and its published action plan is a welcome 
contribution to raising R&D investment in the UK and creating the climate 
and the financial wherewithal for business growth. (Paragraph 107)
28. On the basis of the evidence we have received relating to the Patient Capital 
Review, relaxation of the rules on the allocation of pension fund assets to 
invest in patient capital projects could transform the availability of capital to 
the UK life sciences industry. (Paragraph 111)
29. HM Treasury’s continuing engagement in the implementation and further 
development of the Industrial Strategy in general and its implications for the 
Life Sciences Industrial Strategy will be critical. This engagement will include 
not only promoting the availability of funds but also the establishment of a 
competitive fiscal environment. We recommend that the Treasury should 
report regularly to Parliament on progress. (Paragraph 112)
30. We further conclude that the implementation of HM Treasury’s response 
to the Patient Capital Review and the implementation of the Sector Deals, 
particularly in Life Sciences, needs to be co-ordinated to be effective. This 
might be achieved by the Patient Capital Review implementation team 
being represented on the Life Sciences Governing Body (see paragraph 49). 
(Paragraph 113)
31. The implementation of the Life Sciences Industrial Strategy and the 
Government’s commitment to raise R&D investment to 2.4% of GDP 
by 2027 are closely intertwined. We recommend that the Government 
consults widely in the life sciences and other sectors before publishing plans 
to implement the 2.4% commitment and that the delivery plan for R&D 
investment is coordinated with the implementation plan for the Life Sciences 
Industrial Strategy. (Paragraph 114)
32. We welcome the Government’s commitment to raising R&D investment 
in the UK to 2.4% of GDP by 2027and the emphasis it has been given. 
We look forward to the Government’s plan for delivering the increase. 
(Paragraph 123)
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33. We recommend that the Government should review ways to increase further 
the attractiveness of the UK as a location for business investment in R&D, 
not least in the life sciences. We recommend that the review should include 
benchmarking of UK tax incentives against those in other research-intensive 
nations. We also recommend that the review should develop proposals for 
close cooperation between UK Research and Innovation, the Department 
for International Trade and the Department for Business, Energy and 
Industrial Strategy in attracting higher levels of foreign direct investment in 
R&D. (Paragraph 124)
34. We recommend that the Government should review both the opportunities 
for training scientists and clinicians in business and entrepreneurial skills, 
and for encouraging members of the financial sector to develop sufficient 
understanding of the basics of the science and technology in which they are 
investing their clients’ money. (Paragraph 131)
Skills and training
35. The Government and UK Research and Innovation should promote and 
expand the Rutherford Fund, aligning its objectives with those of the Life 
Sciences Industrial Strategy where appropriate. (Paragraph 144)
36. Immigration policy is central to the continued success of the UK life sciences 
sector. Any inhibition of free movement arising from Brexit will add urgency 
to the case for reform. The Department for Business, Energy and Industrial 
Strategy should assess what is required in the way of scientific talent from 
overseas and work with the Home Office to ensure that immigration 
regulations can facilitate this. Furthermore, we recommend that the body 
responsible for implementing the Life Sciences Industrial Strategy should 
include senior representation from the Home Office so that immigration 
policy can be incorporated into implementation plans. (Paragraph 145)
37. We welcome Sir John Bell’s recommendations on the need to deliver a skilled 
workforce for the life sciences sector. However, without a clear implementation 
plan the chances of action in this area, which requires cross-departmental 
coordination, seem slim. Progress will require the full cooperation of and 
support from the Department for Education. We therefore recommend that 
the membership of the Life Sciences Governing Body should include a senior 
representative from the Department for Education. (Paragraph 163)
38. While further education has an important role in developing the full range of 
skills, the further education sector has had a low profile in the Life Science 
Industrial Strategy and in ministerial announcements on the Industrial 
Strategy more widely. We welcome the Government’s announcement of the 
establishment of new Institutes for Technology. Closer integration of further 
and higher education in the implementation of the Life Sciences Industrial 
Strategy would be welcome. We recommend that the Department for 
Business, Energy and Industrial Strategy and the Department for Education 
publish a joint statement on the relationship between higher and further 
education in the implementation of the strategy. (Paragraph 164)
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39. Incremental development and strengthening of further education will not 
provide the boost needed to address the skills challenges identified in evidence 
to this inquiry. We recommend that the Department for Education promote 
stronger and more varied relationships between the further education sector 
and the business community, for example by creating the further education 
equivalent of the widely praised Higher Education Innovation Fund that 
has done so much to enhance university-business relationships over the last 
decade. (Paragraph 165)
Scientific excellence
40. Increasing investment in the regions of the UK should not be at the expense of 
the golden triangle; the concentration of excellence in the south-east attracts 
private-sector investment. Such investment is essential to the Government’s 
commitment to raise R&D levels to 2.4% of GDP by 2027. (Paragraph 178)
41. We recommend that UK Research and Innovation should include in its 
published strategy a commitment to maintaining the UK’s position as one of 
the world top three nations in scientific discovery in the life sciences sector. 
(Paragraph 182)
42. We support the Government’s efforts to improve the geographical spread 
of excellent research throughout the UK. Clusters containing universities, 
teaching hospitals, and companies large and small can help drive the success 
of the life sciences sector. The Government should identify clusters of 
excellence and encourage their growth. (Paragraph 183)
43. We recommend that the Government implements in full the recommendations 
of the EY review of Catapults that are relevant to the Life Sciences. 
(Paragraph 187)
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* The Rt Hon the Lord Heseltine CH QQ 143–152
* Sir John Chisholm, Executive Chair, Genomics England QQ 153–159
** Professor Dame Ottoline Leyser, Fellow, Royal Society
* Professor Chris Whitty, Chief Scientific Adviser, 
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Coordination of Health Research (OSCHR)
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Research and Innovation (UKRI)
QQ 239–254
** Professor Tim Evans, National Director of Clinical 
Productivity, NHS Improvement
QQ 255–261
** Miles Scott, Improvement Director, NHS Improvement
** Dr Mark Downs CSci FRSB, Chief Executive, Royal 
Society of Biology
QQ 262–271
** Professor Paul Kellam, Chair-Elect of the Policy 
Committee, Microbiology Society
* John Bassett, Policy and Scientific Development Director, 
Institute of Food Science and Technology
** The Rt Hon the Lord Henley, Parliamentary Under-
Secretary of State, Department for Business, Energy and 
Industrial Strategy (BEIS)
QQ 272–285
** The Lord O’Shaughnessy, Parliamentary Under-
Secretary of State, Department of Health and Social Care
** Professor Tony Young, National Clinical Director, 
Innovation NHS England
QQ 286–295
Alphabetical list of all witnesses
AbbVie LSI0068
** Academy of Medical Sciences (AMS) (QQ 54–59) LSI0107
AHSN (Academic Health Science Networks) Network LSI0028
Alan Turing Institute LSI0080
* Albion Capital (QQ 127–134)
Alzheimer’s Research UK LSI0024
** American Pharmaceutical Group (APG) (QQ 180–196) LSI0110
Arthritis Research UK LSI0057
Association of British Healthcare Industries (ABHI) LSI0091
** Association of Medical Research Charities (AMRC) 
(QQ 46–53)
LSI0098
** Association of the British Pharmaceutical Industry 
(ABPI) (QQ 46–53)
LSI0102
Association of UK University Hospitals (AUKUH) LSI0081
Asthma UK LSI0051
** AstraZeneca (QQ 22–26) LSI0117
* AXA Framlington Biotech Fund (QQ 127–134)
Babraham Research Campus (BRC) LSI0086
58 LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
Dr Geoff Baldwin LSI0005
* Professor Sir John Bell, Regius Professor of Medicine, 
University of Oxford and Chair, Office for Strategic 
Coordination of Health Research (OSCHR)  
(QQ 197–238)
Dr David Bennett LSI0019
* BioCity Nottingham Ltd (QQ 135–142)
** BioIndustry Association (BIA) (QQ 46–53) LSI0017
Birmingham Health Partners LSI0034
Bristol BioDesign Institute (BBI) LSI0027
British Academy LSI0095
British Heart Foundation LSI0023
British In Vitro Diagnostics Association (BIVDA) LSI0030
British Pharmacological Society (BPS) LSI0087
British Society for Immunology LSI0072
* Cambridge Enterprise (QQ 135–142)
Campaign for Science and Engineering (CaSE) LSI0076
** Cancer Research UK (CRUK) (QQ 1–8) LSI0097
** Cell and Gene Therapy Catapult (QQ 78–93) LSI0108
Centre for Process Innovation Limited (CPI) LSI0092
Clinigen Group plc LSI0013
Antonio Cunha LSI0008
** Deep Science Ventures (DSV) (QQ 127–134) LSI0093
** Department for Business, Energy and Industrial Strategy 
(BEIS) (QQ 272–285)
LSI0111
LSI0132
** Department of Health and Social Care (QQ 160–167; 
QQ 272–285)
LSI0132
Duchenne UK LSI0036
* Engineering and Physical Sciences Research Council 
(EPSRC) (QQ 1–8)
Enterprise M3 Local Enterprise Partnership LSI0016
F1000 LSI0006
Faculty of Pharmaceutical Medicine (FPM) LSI0085
Greg Fletcher LSI0001
Foreign and Commonwealth Office (FCO) LSI0121
** Francis Crick Institute (QQ 60–68; QQ 69–77) LSI0018
Future Care Capital LSI0120
GARNet LSI0060
59LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
GE Healthcare LSI0065
Genetic Alliance UK LSI0079
* Genomics England and Royal Society (QQ 153–159)
** GSK (QQ 22–26) LSI0115
* The Rt Hon the Lord Heseltine CH (QQ 143–152)
* High Value Manufacturing Catapult (QQ 78–93)
** Dr Michael Hopkins, Sussex University (QQ 168–179) LSI0127
** Imperial College London (QQ 9–14) LSI0112
* Industrial Strategy Commission (QQ 168–179)
** Inhealthcare Ltd (QQ 27–31) LSI0062
** Innovate UK (QQ 78–93) LSI0011
* Institute for Food Science and Technology (QQ 262–271)
Intuitive Surgical Inc. LSI0047
John Innes Centre LSI0089
King’s College London LSI0070
King’s Health Partners LSI0066
Law Society of England and Wales LSI0074
Leeds City Region Medical Technologies LSI0003
Dr Paul Lewis, King’s College London LSI0007
Life Sciences Scotland Industry Leadership Group LSI0042
Lilly UK LSI0106
Loughborough University LSI0033
Tom Macfarlane LSI0094
** Manchester University NHS Foundation Trust  
(QQ 39–45)
LSI0122
MAP BioPharma LSI0090
** Matoke Holdings Ltd (QQ 27–31) LSI0021
LSI0123
MedCity LSI0032
medConfidential LSI0053
* Medical Research Council (MRC) (QQ 1–8)
Medical Schools Council (MSC) LSI0081
Medical Technology Group (MTG) LSI0025
** Medicines Discovery Catapult (QQ 78–93) LSI0116
* Medicines and Healthcare Regulatory Agency (MHRA) 
(QQ 32–38)
Medtronic LSI0039
60 LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
Merck LSI0118
** Microbiology Society (QQ 262–271) LSI0131
Paul Milton LSI0056
** MSD (QQ 180–196) LSI0100
National Anti-Vivisection Society LSI0044
** NHS England (QQ 94–109); (QQ 286–295) LSI0114
** NHS Improvement (QQ 255–261) LSI0128
NHS Innovations South East LSI0010
** NICE (National Institute for Health and Care 
Excellence) (QQ 32–38)
LSI0031
Northern Health Science Alliance (NHSA) LSI0105
* Norwich Research Park (QQ 135–142)
Novartis LSI0075
** Sir Paul Nurse, Francis Crick Institute (QQ 60–68)
Nutrition Society LSI0035
P3 Medical Ltd LSI0029
People for the Ethical Treatment of Animals Foundation 
(PeTA)
LSI0043
Pfizer UK LSI0022
PHG Foundation LSI0048
PhoreMost Ltd LSI0045
PraxisUnico and AURIL LSI0071
Quadram Institute Bioscience LSI0020
Queen Mary University of London LSI0082
Queen’s University Belfast LSI0083
QuintilesIMS LSI0104
** Randox Laboratories Ltd (QQ 27–31) LSI0063
** Research Councils UK (RCUK) (QQ 15–21) LSI0113
Richmond Pharmacology LSI0046
Roche LSI0073
** Rothamsted Research (QQ 110–126) LSI0124
** Royal Academy of Engineering (RAEng) (QQ 54–59) LSI0096
Royal College of Paediatrics and Child Health (RCPCH) LSI0026
Royal College of Physicians (RCP) LSI0040
Royal Microscopical Society LSI0038
Royal Pharmaceutical Society LSI0041
61LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
** Royal Society (QQ 153–159) LSI0119
LSI0126
Royal Society for the Prevention of Cruelty to Animals 
(RSPCA)
LSI0014
** Royal Society of Biology (RSB) (QQ 262–271) LSI0101
LSI0130
Royal Society of Chemistry LSI0049
* Royal Society of Edinburgh (QQ 54–59)
* Royal Veterinary College (QQ 110–126)
Russell Group LSI0109
* Schroders PLC (QQ 127–134)
Scottish Universities Life Sciences Alliance (SULSA) LSI0037
Shelford Group LSI0103
Shire Pharmaceuticals LSI0084
** Syngenta (QQ 110–126) LSI0125
Thermo Fisher Scientific LSI0012
UCLPartners LSI0059
UK Centre for Animal Law LSI0061
** UK Research and Innovation (UKRI) (QQ 239–254) LSI0129
** University College London (UCL) (QQ 9–14) LSI0058
* University College London Hospitals (QQ 39–45)
* University Hospitals Birmingham NHS Foundation Trust 
(QQ 39–45)
* University of Cambridge (QQ 9–14)
University of East Anglia LSI0088
University of Glasgow LSI0009
University of Leeds LSI0069
University of Manchester LSI0078
** University of Nottingham (QQ 9–14) LSI0067
University of Oxford LSI0054
University of Southampton, Institute for Life Sciences LSI0050
University of Surrey LSI0077
Urology Trade Association (UTA) LSI0099
* Wellcome Trust (QQ 1–8)
WideCells Group PLC LSI0004
62 LIFE SCIENCES INDUSTRIAL STRATEGY: WHO’S DRIVING THE BUS?
APPENDIX 3: CALL FOR EVIDENCE
The House of Lords Science and Technology Select Committee, under the 
Chairmanship of Lord Patel, is conducting an inquiry into Life Sciences and the 
Industrial Strategy. The Committee invites interested individuals and organisations 
to submit evidence to this inquiry. The deadline for written evidence submissions 
is Friday 15 September 2017.
Background
The UK life sciences sector is high-tech, research-intensive, diverse and innovative. 
According to one analysis, it contributed £30.7bn to the economy in 2015 and 
supports a total of 482,000 jobs.226 However, to tackle challenges like cancer and 
dementia it is important that the UK continues to have a strong life sciences sector. 
The sector faces a number of challenges and opportunities, including Brexit, with 
much of the regulation of the sector coming from the EU. In this context, as part 
of its wider work on an Industrial Strategy the Government has asked Sir John Bell 
to carry out work on a Life Sciences strategy and a ‘sector deal’ for life sciences.227 
The Industrial Strategy green paper states that Sir John will lead work on a “new 
strategy to make the UK the best place in the world to invest in life sciences”.228 It 
is unclear how the relative attractiveness of the UK to life science investors will 
be assessed. The Committee is launching this inquiry now to contribute to the 
discussion around the strategy and the role of the Government and business in its 
development and implementation.
Scope
The Committee’s inquiry will consider the upcoming life sciences industrial 
strategy, which the Government asked Sir John Bell to work on as part of its 
wider industrial strategy. The new life sciences industrial strategy is expected 
to be published during the period in which this call for evidence is open and 
the Committee would welcome the views of respondents on the contents of the 
strategy.
The Coalition government published a UK Life Sciences strategy in 2011, which was 
subsequently re-launched in 2013. The 2011 Life Sciences Strategy containing a 
number of “key actions”. These included an early access scheme for innovative new 
therapies, a £310m investment to support the commercialisation of research, an 
enhanced UK clinical trials gateway and a number of high-level apprenticeships. 
The Committee will investigate the impact of this strategy and what lessons can 
be learned for the new strategy.
George Freeman MP served as a dedicated life sciences minister from 2014–16. 
However, he was not replaced in July 2016. Responsibility for Life Sciences is now 
split between Lord O’Shaughnessy in the Department of Health and Lord Prior in 
the Department of Business, Energy and Industrial Strategy. Both ministers also 
have other ministerial responsibilities. The Committee will investigate whether 
the Government has the necessary structures in place to support the life sciences 
sector and the life sciences industrial strategy. Furthermore it will look at how the 
devolved administrations will be involved in the implementation of the strategy.
226 PwC, The Economic contribution of the UK Life Sciences industry (March 2017): https://www.abpi.org.uk/
media/1371/the_economic_contribution_of_the_uk_life_sciences_industry.pdf 
227 HM Government, Press release: ‘PM unveils plans for a modern Industrial Strategy fit for Global 
Britain’, 22 January 2018: https://www.gov.uk/government/news/pm-unveils-plans-for-a-modern-
industrial-strategy-fit-for-global-britain 
228 Department for Business, Energy & Industrial Strategy, Building our Industrial Strategy
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In 2014 the Government commissioned the Accelerated Access Review to look 
into speeding up access to innovative drugs, devices, diagnostics and digital 
products for NHS patients. The review was independently chaired by Sir Hugh 
Taylor and supported by the Wellcome Trust. In October 2016 the review 
published its final report. The Government has yet to respond to the report and its 
recommendations. The Committee will investigate how these recommendations 
can be implemented alongside the life sciences industrial strategy and broader 
issues around the collaboration between researchers and the NHS and how the 
NHS can use procurement to stimulate innovation in the life sciences sector.
In its previous work on the Industrial Strategy green paper the Committee heard 
evidence that there is a problem with the availability of patient capital in the UK 
for developing innovations and growing new companies. The Prime Minister 
announced a Patient Capital Review in November 2016, to be led by HM Treasury, 
which “will identify barriers to access to long-term finance for growing firms. The 
Committee will further investigate this problem, with particular focus on the life 
sciences sector.
Questions
The Committee invites submissions on the following points, with practical 
examples and other evidence where possible. Please only answer those questions 
of relevance to you. The Committee is very much interested in views from both 
within and outside the life sciences sector. Please also do draw the Committee’s 
attention to any relevant issues not captured in the specific questions below:
Science and innovation
1. How can investors be encouraged to invest in turning basic life science 
research into new innovations in treatment? Why has investment been lacking 
in this sector? Does the research base have the necessary infrastructure to be 
world-leading?
2. Why has the UK underperformed in turning basic research in the life 
sciences into intellectual property? What needs to be done to address this 
historic weakness in the UK and grow new companies to commercialise new 
research and related technologies in the life sciences?
3. What can be done to ensure the UK has the necessary skills and manpower 
to build a world class life sciences sector, both within the research base and 
the NHS?
4. How does the UK compare to other countries in this sector, for example 
Germany and the United States?
Industrial Strategy
5. What can be learnt from the impact of the 2011 UK Life Sciences Strategy? 
What evidence is there that a strategy will work for the life sciences sector? 
How can its success be measured against its stated objectives?
6. (If published) Does the strategy contain the right recommendations? 
What should it contain/what is missing? How will the life sciences strategy 
interact with the wider industrial strategy, including regional and devolved 
administration strategies? How will the strategies be coordinated so that they 
don’t operate in ‘silos’?
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7. What opportunities for small and medium sized enterprises (SMEs) are there/
should there be in the strategy? How can they be involved in its development 
and implementation?
8. Where should the funding come from to support the implementation of the 
strategy?
9. How do the devolved administrations and city regions fit into the strategy? 
Scotland has its own life sciences strategy, how will the two interact?
NHS procurement and collaboration
10. How can public procurement, in particular by the NHS, be an effective 
stimulus for innovation in the Life Sciences Sector? Can it help support 
emerging businesses in the Life Sciences sector?
11. How can the recommendations of the Accelerated Access Review be taken 
forward alongside the strategy? Will the recent changes to the NHS England 
approval process for drugs have a positive or negative effect on the availability 
of new and innovative treatments in the NHS? How can quick access to new 
treatments and the need to provide value for money be reconciled?
12. How can collaboration between researchers and the NHS be improved, 
particularly in light of increased fiscal pressures in the NHS? Will the NHS 
England research plan help in this regard? How can the ability of the NHS to 
contribute to the development of and adopting new technology be improved?
Responsibility and accountability?
13. Who should take responsibility for the implementation of the Life Sciences 
Industrial Strategy and to whom should they be accountable? What should 
the UK Government’s role be? What should the role of the academic, 
charitable and business sectors be?
14. What is the role of companies within the sector, particularly the large 
pharmaceutical companies, in the implementation of the strategy? How are 
they accountable for its success?
15. Does the Government have the right structures in place to support the 
life science sector? Is the Office of Life Sciences effective? Should the 
Government appoint a dedicated Life Sciences Minister? If so, should that 
Minister have UK-wide or England-only responsibilities?
Brexit
16. What impact will Brexit have on the Life Sciences sector? Will the strategy 
help the sector to mitigate the risks and take advantage of the opportunities 
of Brexit?
17. How should the regulatory framework be changed or improved after Brexit 
to support the sector?
18. To what extent should the UK remain involved with and contribute to 
agencies such as the EMA post Brexit?
21 July 2017
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APPENDIX 4: SEMINAR HELD AT THE HOUSE OF LORDS ON 12 
SEPTEMBER 2017
Members of the Committee present were Lord Patel (Chairman), Lord Borwick, 
Lord Fox, Lord Griffiths of Fforestfach, Lord Kakkar, Lord Mair, Lord Maxton, 
Baroness Neville-Jones, Lord Oxburgh, Lord Vallance of Tummel and Baroness 
Young of Old Scone.
Presentations were heard from:
• Dr Menelas Pangalos, Executive Vice-President of AstraZeneca’s Innovative 
Medicines and Early Development Biotech Unit, AstraZeneca;
• Lord Macpherson of Earl’s Court, former Permanent Secretary HM 
Treasury, 2005–16;
• Professor Graeme Reid, Professor of Science and Research Policy, University 
College London (UCL);
• David Levinger, CEO, Aura Capital Partners and Head of Operations, 
Institute for Strategy, Resilience & Security, UCL; and
• Professor Steve Jackson, FRS, FMedSci is the University of Cambridge 
Frederick James Quick and Cancer Research UK Professor of Biology.
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APPENDIX 5: COMMITTEE VISIT TO THE FRANCIS CRICK 
INSTITUTE ON 31 OCTOBER 2017
Members of the Committee present were Lord Patel (Chairman), Lord Borwick, 
Lord Fox, Lord Hunt of Chesterton, Lord Mair, Lord Maxton, Lord Oxburgh, 
Lord Renfrew of Kaimsthorn, Lord Vallance of Tummel and Baroness Young of 
Old Scone.
Members heard evidence from Sir Paul Nurse, Director and Chief Executive 
of the Francis Crick Institute. They heard further evidence from Dr Veronique 
Birault, Head of Translation, Dr Simon Boulton, Senior Group Leader, Professor 
Charles Swanton, Senior Group Leader, Dr Kathy Niakan, Group Leader, and 
Dr Caetano Reis e Sousa, Senior Group Leader at the Francis Crick Institute.
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APPENDIX 6: ABBREVIATIONS, ACRONYMS AND TECHNICAL 
TERMS
ABHI Association of British Healthcare Industries
ABPI Association of the British Pharmaceutical Industry
AHSN Academic Health Science Network
APG American Pharmaceutical Group
AUKUH Association of the UK University Hospital
BEIS Department for Business, Energy and Industrial Strategy
BIA UK BioIndustry Association
DARPA Defence Advanced Research Projects Agency
DHSC Department of Health and Social Care
EIS Enterprise Investment Scheme
EU European Union
HARP Health Advanced Research Programme
HEFCE Higher Education Funding Council for England
ISCF Industrial Strategy Challenge Fund
MSC Medical Schools Council
NHS National Health Service
OfIS Office for Industrial Strategy
R&D Research and Development
REF Research Excellence Framework
SBRI Small Business Research Initiative
SEIS Seed Enterprise Investment Scheme
SMEs Small and Medium Sized Enterprises
STEM Science, Technology, Engineering and Mathematics
UKRI UK Research and Innovation
VCTs Venture Capital Trusts
